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ABSTRACT 
 
Abnormalities in retinal vascular permeability can result in macular edema, the buildup 
of fluid in the retina, which causes the retina to swell and thicken, and leads to neuronal cell 
death and vision loss. Increased retinal vascular permeability is found in many eye pathologies, 
including diabetic retinopathy (DR), age-related macular degeneration (AMD), and retinal vein 
occlusion (RVO). The pathological changes in vascular permeability are driven by elevated 
levels of growth factors such as vascular endothelial growth factor (VEGF) and pro-
inflammatory cytokines such as tumor necrosis factor (TNF-α). The use of VEGF-neutralizing 
antibodies as a form of treatment improves vision in about half of patients treated. However, 
these treatments are invasive, secondary complications are observed, and half of the patients 
treated do not improve. Therefore, understanding mechanisms that block vascular permeability 
and restore the blood-retinal barrier (BRB) are important for developing novel therapies 
promoting barrier restoration.  
The small guanosine triphosphatase (GTPase) Rap1 and its guanine-nucleotide-exchange 
factor (GEF), EPAC, have been identified as key regulators of barrier formation, promoting cell-
cell adhesion, cell-extracellular matrix (ECM) adhesion, and the assembly of junctional 
complexes in human umbilical vein endothelial cells (HUVEC) and epithelial cells. However, it 
is unknown whether the EPAC-Rap1 signaling pathway regulates the tight junctions (TJs) of 
retinal endothelial cells and the relationship between EPAC-Rap1 and VEGF signaling in retinal 
permeability is poorly understood. The goals of this thesis are to: 1) determine whether EPAC-
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Rap1 signaling regulates the barrier properties of the BRB, and 2) gain insight into the 
mechanisms of endothelial cell permeability to identify novel therapeutic targets. 
To investigate the role of EPAC-Rap1 signaling in the BRB, EPAC was activated using 
the membrane permeable cAMP analog, 8-pCPT-2´-O-Me-cAMP-AM (8CPT-AM). 8CPT-AM 
treatment blocked and, importantly, reversed permeability induced by VEGF and TNF-α both in 
vivo and in vitro and promoted TJ organization in bovine retinal endothelial cells (BREC). 
Additionally, inhibition of EPAC2 or knockdown of Rap1B led to an increase in basal 
permeability. Rap1B knockdown alone recapitulated the TJ disorganization observed with 
VEGF. Furthermore, pretreatment of cells with 8CPT-AM prior to VEGF, decreased VEGF-
induced phosphorylation of VEGFR2 and Erk1/2. Together, these data show that activation of 
EPAC-Rap1 signaling can promote and restore barrier properties by blocking permeability 
inducing agents, attenuate VEGF-Erk1/2 signaling, and promote organization of the TJ complex.      
To further explore and gain insight into the mechanisms of VEGF signaling in retinal 
endothelial permeability, mass-spectrometry based phosphoproteomics was performed on BREC.  
1,724 proteins were identified. From these proteins, 107 phosphoproteins that had a 25% 
phosphorylation change in the presence of VEGF and were present in more than one mass 
spectrometry analysis were identified and used to develop protein interaction networks using 
Cytoscape. One of the protein interaction networks obtained consists of the proteins EPAC, 
rasip1, and afadin (AF-6), all of which show significant changes in phosphorylation in the 
presence of VEGF. 
The results presented here provide new evidence that EPAC-Rap1 signaling contributes 
to the barrier properties of the BRB via regulation of the TJ complex. Additionally, the 
phosphoproteome analysis suggests how VEGF may increase permeability through 
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phosphorylation and regulation of the EPAC/Rap/rasip1 pathway. Overall, the results from this 
thesis expand our knowledge on the role of EPAC2 and Rap1B in regulating retinal endothelial 
barrier properties and permeability. Further, these data identify specific targets for novel 
therapies addressing abnormalities in retinal vascular permeability.    
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CHAPTER 1 
Introduction* 
 
1. 1 Barriers of the Central Nervous System 
In 1885, Paul Ehrlich published the first observation of a Central Nervous System (CNS) 
barrier. Ehrlich observed that water-soluble dyes, injected subcutaneously, stained all organs 
except the brain and spinal cord [1]. It was not until 1900 that the concept of a CNS barrier was 
introduced by Lewandosky who termed it “capillary wall.” Later, in 1918, the term “barrier” was 
proposed by Lina Stern [2]. The pioneering work performed by Ehrlich, Lewandosky, Stern and 
other scientists led to the recognition of the blood-brain barrier (BBB). 
The earliest observations of the blood-retinal barrier (BRB) were reported by Schnaudigel 
in 1913 and Palm in 1947. Intravenous injection of trypan blue into rabbits stained all organs, but 
not the CNS or the retina [3]. These initial observations were later supported at the ultrastructural 
level by Cunha-Vaz [4, 5]. Thus, the BBB and the BRB were discovered to form part of the 
barriers of the CNS. We now understand that the BBB and BRB provide tight control of the 
neuronal environment by regulating the flux of blood borne material into the neural parenchyma. 
These barriers maintain proper neural homeostasis and protect the neural tissue from potential 
blood-borne toxicity.  
 
 
*Note: Portions of this introduction were published previously in two articles entitled, “The inner blood-retinal barrier: 
Cellular basis and development” (Díaz-Coránguez et al., 2017) and “The role of small GTPases and EPAC-Rap1 signaling 
in the regulation of the blood-brain and blood-retinal barriers” (Ramos and Antonetti, 2017). 
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Understanding how barriers of the CNS develop in order to supply the required metabolic 
support for neural tissue and sustain the proper environment for synaptic signaling remains an 
area of active investigation. The vasculatures in both the brain and retina have well-developed 
tight junction (TJ) complexes, which restrict paracellular flux by maintaining precise control of 
proteins, metabolites and cells that can enter the neural tissue. Additionally, these vascular 
endothelial cells exhibit limited fenestrae and low endocytic vesicle formation in order to 
maintain a tight barrier [6, 7].   
Loss of these barriers is observed in a variety of pathologies associated with high 
morbidity and mortality. Brain tumors, dementia, Alzheimer’s disease, Parkinson’s disease, and 
a host of blinding eye diseases such as diabetic retinopathy, retinal vein occlusions, retinopathy 
of prematurity and age-related macular degeneration all have a “leaky” vascular barrier [6, 8, 9]. 
Vascular permeability involves both increased paracellular flux associated with changes in the 
cell junctional complexes that connect adjacent cells and increased transport through the 
transcellular pathway mediated by endocytic vesicles. 
1.2 The Retinal Vasculature 
The retina is a thin, highly organized, multi-layered and multi-cellular neural tissue 
responsible for vision. It is located on the posterior cavity of the eye between the choroid and the 
vitreous humor (Figure 1.1.A). The retina’s function is to capture light stimuli and convert it into 
an electrical impulse that can be transmitted, via the optic nerve, to the brain’s visual cortex and 
ultimately interpreted as visual input. 
The retina, like the brain, is a high energy demanding system in the body because of 
neuronal activity [10]. However, the retina also requires low intra-retinal blood vessels in order 
to allow vision. Two vascular beds satisfy these competing requirements. The retina is divided 
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into two main parts, the inner and the outer retina (Figure 1.1.B). The inner retina consists of 
three layers: the ganglion cell layer (GCL), the inner plexiform layer (IPL) and the inner nuclear 
layer (INL) (Figure 1.1.B). The outer retina extends from the outer plexiform layer (OPL), 
through the outer nuclear layer (ONL) to the retinal pigment epithelium (RPE) (Figure 1.1.B). 
The outer retina is avascular and contains photoreceptors which are highly oxygen demanding 
and consumes 8% of the basal metabolic rate [11, 12]. In order to support the demands from the 
different retinal regions, the retina has a dual blood supply system, which arises from the central 
retinal artery circulation [13]. The inner retina is nourished by the retinal vasculature, which 
provides nutritional support and waste product removal (Figure 1.2). The oxygen levels of the 
inner retina are regulated and maintained at a relative hypoxic state, PO2 of 20mmHg [14]. The 
retinal vasculature is further divided into the inner superficial vasculature and the deep 
vasculature. The inner superficial vasculature is located at the GCL and the deep vasculature is 
located at the inner and outer edges of the inner nuclear layer (INL) (Figure 1.2) [13]. The outer 
retina is nourished by the choroidal vasculature separated from the retina by the RPE which 
controls metabolic nourishment and waste removal (Figure 1.1.B) [13].  
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Figure 1.1 Anatomy of the Retina. A. Schematic of the human eye and localization of 
the retina. B. Schematic of retina cross section enlargement showing cell types and 
layers. The red arrows show the retinal vasculature of the inner retina and the red circle 
in the choroid layer shows the choroidal vasculature of the outer retina (adapted from 
Antonetti et al., 2012). 
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1.2.1 Development of the Retina Vasculature 
In early human retinal development, a hyaloid network of vasculature emerges from the 
central hyaloid artery in the optic nerve, providing vascular support for the whole eye. In 
humans, hyaloid vessels regress and the retinal vasculature begins developing around week 14 of 
gestation (WG) and continues until the day of birth [15]. The retinal vasculature development is 
conducted by two different mechanisms: vasculogenesis, which refers to the maturation of 
progenitor cells to the primary vascular bed; and angiogenesis, which is the sprouting of vessels 
from the pre-existing vasculature. 
In humans, retinal vasculogenesis occurs from WG 14 to WG 18. Vasculogenesis is 
followed by angiogenesis at WG 18 [15]. The primary sprouts come from the optic nerve head 
and expand radially along the vitreal surface in the retina, attracted by the VEGF secreted from 
astrocytes. In the primary plexus, the differentiation of major arteries and veins takes place, 
followed by sprouting into the deep retinal tissue. At WG 21, the first capillary bed in the outer 
layer is apparent, and the sprouting continues to the inner plexus in a process that coincides with 
the eye opening. In humans, this process culminates by WG 32, when hyaloid vasculature 
regression has been completed. 
However, much of our understanding of retinal vascular development comes from mice, 
whose hyaloid regression and retinal vascular development begins after birth. In mice, retinal 
angiogenesis starts at the day of birth, as does the formation of the superficial plexus that covers 
the retinal surface by post-natal day 8 (P8). This is followed by vascular sprouting into the deep 
and intermediate plexus layers, formed at P7–P12 and P14–P21, respectively. 
Retinal angiogenesis is mainly governed by the expression of the VEGF receptor 
(VEGFR2), which regulates endothelial migration and proliferation in response to VEGFA 
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secreted by glia and neurons [16, 17]. During the angiogenic process, two endothelial cell types 
can be distinguished: endothelial tip cells, which establish the direction of the sprouting by 
extending their filopodia toward the VEGF source; and stalk cells, an intermediate population of 
cells in the vascular plexus that proliferate and extend the length of the vessels. Tip cells express 
delta like 4 (Dll4), Platelet Derived Growth Factor Subunit B (PDGFB) and apelin ligands [18-
20], while the netrin receptor Unc5b and VEGFR are upregulated in stalk cells [21, 22]. 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 The Retinal Vasculature. Immunofluorescence staining using IB4 (pink) was 
used to detect the retinal vasculature in a rat retina cross section. The inner superficial 
vasculature is observed in the ganglion cell layer (GCL). The deep vasculature is at the 
inner and outer edges of the inner nuclear layer (INL). 
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1.3 Blood-Retinal Barrier 
   The retina, similar to the brain possesses a blood-retinal barrier. Structurally, the BRB 
consists of two distinct barriers, the outer BRB (oBRB) and the inner BRB (iBRB). The oBRB 
consists of the retinal pigment epithelium (RPE) that regulates movement from the choroidal 
vasculature to the inner retina. The iBRB is comprised of the retinal endothelial cells, astrocytes, 
and pericytes all which form the neurovascular unit. The iBRB provides oxygen and glucose for 
neuronal function and regulates transport of ions, nutrients, and toxins across the retinal 
capillaries [23, 24]. Loss of the iBRB contributes to the pathophysiology of a number of retinal 
diseases, including diabetic retinopathy [23, 25].  
1.3.1 Flux and Permeability 
The CNS barriers are highly selective, regulating the movement of ions, water, solutes 
and cells across capillaries [26]. Flux of a solute or water is defined as the net movement across a 
barrier over time, while permeability describes the property of the barrier, in this case, of the 
iBRB. 
Fluid flux is the movement from the lumen of capillaries into the interstitial space. 
Starling’s principle describes the net fluid flux (Jυ) across the capillary membrane as the 
difference between the hydrostatic pressure and oncotic pressure. This was later modified to 
include the permeability of the endothelium barrier, recognizing that different vascular beds 
possess differences in barrier properties [27]. Thus, the net movement of fluid flux across a semi-
permeable membrane can be calculated by the equation below, where Jυ= net fluid flux (ml/min); 
Kf = the filtration coefficient (ml/min/mmHg); Pc = the capillary hydrostatic pressure (mmHg); 
Pi = the interstitial hydrostatic pressure (mmHg); σ = the reflection coefficient; πc = the 
capillary oncotic pressure (mmHg); πi = the interstitial oncotic pressure (mmHg): 
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Jυ = Kf ([Pc-Pi] – σ[πc-πi]) 
The filtration coefficient (Kf) is a constant that describes the barrier’s permeability to water. 
The BRB, like the BBB, is less permeable than other vascular beds. The reflection coefficient (σ) 
is a correction factor for the membrane’s permeability to the proteins involved in generating the 
oncotic pressure, i.e. albumin. The capillary hydrostatic pressure refers to the pressure of 
blood/plasma against the vessel walls. The capillary oncotic pressure is a form of osmotic 
pressure exerted by protein content in the blood plasma that absorbs water into the lumen of 
vessels. Studies testing Starling’s principle have demonstrated that changes in the capillary 
oncotic pressure have a minimal effect on fluid filtration across the endothelium. Instead, the 
endothelial glycocalyx layer (EGL) plays a major regulatory role in capillary fluid filtration [28, 
29]. The EGL is a mesh composed of membrane-bound glycoproteins and proteoglycans, located 
on the luminal side of endothelial cells. The EGL is semi-permeable to molecules like albumin 
and impermeable to dextran molecules >70kDa. In the CNS barriers, which are composed of 
non-fenestrated capillaries and continuous basement membrane, the EGL is also continuous.  
On the other hand, permeability (Po), across a barrier to a specified solute can be measured 
by calculating the rate of flux of the molecule. The Po, is calculated by the equation below, where 
Po = diffusive flux (cm/s); [C]A = basolateral concentration of the molecule of interest, often a 
labeled marker; [C]L = apical concentration; ∆t = change in time; A = surface area of the filter 
(cm2); VA = volume of the basolateral chamber (cm3): 
Po = ([C]A VA /∆t)/[C]LA 
Evan’s blue dye, which tightly binds albumin, is often used to quantify the accumulation 
of albumin in the retina over a specified time, and differences in dye accumulation are 
interpreted as changes in permeability.  
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1.3.2 Routes of Permeability  
Changes in permeability across the vascular bed may occur through changes in transport 
across the cells, broadly termed transcytosis, or through changes in the junctional complex 
organization, leading to flux around the cells or paracellular permeability. Both transcellular and 
paracellular routes are composed of multiple pathways that are not mutually exclusive, and may 
collectively contribute to altered flux. 
1.3.2.1 Transcytosis 
In 1960, Palade et al. described invaginations of the plasmalemma in the capillary 
endothelium that ‘‘pinch off” from the surface and form intracellular vesicles [30]. Electron 
microscopy revealed intracellular vesicles and invaginations, which suggested a regulated and 
directional transport [31]. Other groups observed a preference of localization for vesicles on one 
side of the membrane, suggesting a unidirectional flow [32]. However, this idea has been 
challenged by recent studies which reported invaginations on both sides [33]. 
In 1979, Nicolae Simionescu introduced the term transcytosis. In his electron microscopy 
studies, he identified the appearance of highly dense structures that he called specialized 
plasmalemma vesicles within endothelial cells [34]. We now know that transcellular transport 
across retinal endothelial cells is necessary for regulation of the retinal environment’s 
homeostasis. 
There are a variety of routes that make up the transcellular transport [35]. Some small 
lipophilic molecules can passively diffuse along the retinal endothelial membrane and cross the 
BRB [36]. Other, larger, lipophilic molecules and hydrophilic molecules require ATP-dependent 
processes to cross the barrier, including: receptor-mediated vesicular transport, nonreceptor 
mediated pinocytosis, transporters and pumps (Figure 1.3). Brain and retinal endothelial cells 
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selectively regulate the transcellular movement of molecules from the blood to the neural tissue 
by controlling the expression of molecules at both the luminal and abluminal sides. Retinal 
endothelial cells express a low number of receptors, transporters and vesicle formation 
mediators, in combination with a high expression of efflux pumps [37], which collectively 
contribute to the BRB. 
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Figure 1.3 Mechanisms of Transcellular Transport Across Retinal Endothelial 
Cells. Some molecules can cross by diffusion due to their lipophilic properties. Other 
transport mechanisms are energy-dependent processes and include receptor-mediated 
transport, pinocytic vesicles, carrier-mediated transporters, ion transporters and efflux 
pumps. The endothelial cells that constitute the BRB, express a low number of these 
transporter mechanisms, some of the most important are indicated. (Figure from Díaz-
Coránguez, M., et al.2017) 
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1.3.2.2 Paracellular Transport  
In addition to transcellular transport, molecules can move via paracellular transport 
(Figure 1.4), which occurs through the intercellular space between adjacent cells. The 
intercellular space is highly regulated by the formation of junctional complexes, which include 
tight junctions (TJ), adherens junctions (AJ), gap junctions, and desmosomes, with TJs and AJs 
having a central role in barrier regulation. 
 
 
 
 
 
 
 
Figure 1.4 Paracellular Transport. In the BRB, molecules can move from 
the blood (luminal) into the retinal (abluminal) side via the paracellular space, 
which is located in between two adjacent cells (blue line). Some of the 
molecules central to control of paracellular transport of the BRB are indicated. 
(Figure from Díaz-Coránguez, M., et al.2017) 
 
13 
 
1.4 Tight Junctions (TJ) 
In the BRB, the very tight control of solute and fluid flux across the endothelium is conferred 
by a well-developed tight junction complex. Evidence of TJ complexity in these tissues was 
demonstrated in studies of freeze fracture sections and electron microscopy, which unveiled a 
dense network of branch points on tight junction strands [38]. In ultrathin sections of epithelial 
cells, TJs appear as contact points of close apposition, or ‘‘kissing points”, where the two lipid 
bilayers of each neighboring cell are almost indistinguishable; these are located specifically at 
the most apical side of the polarized lateral membrane [39]. In contrast, in endothelial barriers, 
these same contact points are localized at several points along the paracellular space, between 
cells and at cell-cell contacts that form the capillary lumen [40]. The molecular mechanisms that 
regulate the difference in polarization between epithelial and endothelial cells have not yet been 
determined. 
Tight junctions serve two main functions: a gate function that restricts the passage of 
molecules through the paracellular space, and a fence function that confers cell polarity by 
preventing movement of lipids and proteins between the apical and basolateral plasma membrane 
[39, 41, 42]. Additional roles of tight junctions in several cell-signaling processes such as cell 
proliferation, gene expression, and differentiation, have also been described [43-45].  
At a molecular level, the tight junctions consist of over 40 proteins, which can be 
categorized as:1) transmembrane proteins, including the tetraspanin families of claudin and 
MARVEL (MAL and related proteins for vesicle trafficking and membrane link) proteins, and 
the single span proteins from the  junctional adhesion molecules (JAM) family; or 2) cytoplasmic 
scaffold proteins, including members of the membrane-associated guanylate kinase homologue 
(MAGUK) family like zonula occludens (ZO), and other platform proteins such as afadin (AF6) 
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and cingulin [46-48]. 
1.4.1 Claudins  
The claudin family consists of tetraspan transmembrane proteins that play a crucial role 
in paracellular transport by forming ion selective barriers and pores [49, 50]. Claudins range 
between 20-34 kDa and possess cytoplasmic intracellular NH2- and COOH- termini, in addition 
to two extracellular loops [51]. Mutational analyses have revealed that amino acid charges on the 
first extracellular loop of claudins define the ion selective property of these proteins, while the 
second extracellular loop is involved in claudin-claudin interactions [52-55]. In addition, the 
carboxy-terminus of claudins interacts with the first of three PDZ domains on the scaffolding 
protein ZO-1 [56]. This allows the connection between transmembrane proteins and the actin 
cytoskeleton, and controls the localization of claudins at cell contacts. 
Claudins expressed on the plasma membrane of the same cell can polymerize by cis-
interactions into homomeric or heteromeric strands. Homomeric interactions occur between the 
same type of claudin, for example claudin-3 binds to claudin-3. Heteromeric interactions occur 
between different claudin types, for example claudin-3 binds claudin-1 [57]. Claudins in adjacent 
cells (trans-interaction) can also interact with other claudins in a homotypic (same type of 
claudin) or heterotypic (different claudin) fashion. Expression of different claudin isoforms 
yields tissue specific barrier properties. Indeed, claudins are subdivided into sealing claudins and 
pore-forming claudins that are ion-specific paracellular channels [58]. Moreover, overexpression 
of claudin in non-tight junction-forming cells like fibroblasts, leads to formation of a tight 
junction-like network [51, 59], supporting the important role of claudins in tight junction 
formation between adjacent cells. 
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There are 27 known mammalian claudin members, 26 of which are found in humans [60, 
61]. Measurements of mRNA in mouse retinas from P18 show expression of several claudins, 
including claudin-1-5, -7, 9-14, 16-17, -19, -20, -22 and -23. Claudin-5 is the most abundant of 
the isoforms, and it localizes at the tight junctions of retinal vessels, together with claudin-1 and -
2 [62]. Claudins-1-5, -12, -22 and -23 are regulated in retinal development. During early to mid-
development, all the claudins mentioned above increase in expression, especially at P15, 
coinciding with the formation of the iBRB in retinal capillaries. After this point, their expression 
decreases, except for claudin-22. Moreover, after oxygen-induced retinopathy at P15 though 
P21, claudin-2 and -5 are overexpressed [62], suggesting that claudins regulate the barrier 
function of retinal endothelial cells. In accordance with the high levels of claudin-5 in both the 
BBB and BRB, claudin-5-deficient mice die within 10 hours after birth due to BBB disruption. 
While these mice show no abnormal development or morphology of blood vessels and no 
abnormal bleeding or edema, they do have a BBB leaky towards small molecules < 800 Da [63]. 
No BRB defects have been reported in mice lacking claudin-5. However, ongoing studies 
focusing on the BRB and the BBB in pathologies that model diabetes, ischemia, and strokes have 
associated loss of claudin-5 with an increase in permeability [64, 65], supporting the important 
role of claudin-5 in BRB. Claudin-1 deficient mice die within the first day of birth due to 
disruption of the skin barrier, however, no BBB or BRB alteration has been reported [51, 66]. 
Nevertheless, some studies suggest that claudin-1 is expressed in the retinal vasculature of adult 
mice, and its content decreases in both streptozotocin (STZ) induced diabetic rats [67], and a 
model of experimental autoimmune uveoretinitis (EAU) [68]. 
Not all retinal claudins are restricted to blood vessels. In contrast to BBB studies, in the 
BRB, there are no reports related to claudin-3 changes in retinal vasculature associated with 
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altered permeability. In fact, claudin-3 in the retina is expressed in the retinal ganglion cell layer 
(RGC) [62]. Likewise, other claudin isoforms were found in non-endothelial retinal tissues. 
Claudin-4 and -23 are localized at the RGC layer, claudin-4 and -12 are expressed in the outer 
plexiform layer (OPL), and claudin-23 was found in the inner nuclear layer (INL) [62]. The roles 
of these claudins in the retinal tissue have not been studied yet. Together, these data suggest that 
claudins, particularly claudin-5, are important in the regulation of the CNS barriers. However, 
additional claudin isoforms that have the potential to regulate BRB properties require further 
investigation. 
1.4.2 MARVEL Proteins 
MARVEL (MAL and related proteins for vesicle trafficking and membrane link) proteins 
contain a conserved four-transmembrane MARVEL domain. The MARVEL proteins are 
characterized by their association with the cell’s plasma membrane and their involvement in 
vesicle trafficking [69]. The tight junction-associated MARVEL protein members involved in 
TJs are part of the TJ-associated MARVEL protein (TAMP) comprised of occludin 
(MARVELD1), tricellulin (MARVELD2), and MARVELD3 [70].  
1.4.2.1 Occludin 
Occludin (MARVELD1), a ~60kD membrane protein, was first identified as a component of 
TJ from chick liver junctional fractions [71]. Hydrophilicity plots and cDNA sequence analyses 
showed that occludin is a tetraspan transmembrane protein that has two extracellular loops and 
cytoplasmic NH2 and COOH termini [71, 72]. The N-terminus of occludin interacts with Itch, an 
E3-ubiquitin-protein ligase that regulates occludin degradation [73] and endocytosis [74]. The 
distal C-terminus of occludin forms a coiled-coil region that binds to the scaffold proteins ZO-1, 
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specifically to the guanylate kinase like (GUK) domain of ZO-1 [75, 76], ZO-2 [77], and ZO-3 
[78].  
Occludin expression correlates with barrier properties. Overexpression of occludin in Madin-
Darby Canine kidney cells (MDCK) causes an increase in trans-epithelial resistance but 
surprisingly not a decrease in solute flux. Truncation of the carboxyl tail causes an increase in 
permeability and tight junction disorganization [79-81]. Likewise, in the BBB and BRB, high 
levels of occludin expression are associated with increased barrier properties of vascular beds 
[82].  
Occludin was once thought to be the main sealing tight junction protein; however, current 
research suggests this protein contributes to regulation of barrier properties, rather than acting 
directly as a structural protein in TJs. Mutations in occludin have recently been associated with 
microcephaly (small head size), brain calcification, polymicrogyria (excessive folding of the 
brain cortex), lack of motor development, reduced vision, and renal involvement in some 
families [83-85]. Knockout of occludin in mice has shown that occludin is not required for tight 
junction formation or basal intestinal epithelial barrier properties [86, 87]. These animals did, 
however, express several abnormalities such as brain calcification, male sterility, inability for 
female mice to nurse, and gastric epithelial hyperplasia [87, 88].  
Recent studies show that occludin has a more complex function than originally thought, 
including the regulation of cell signaling, tight junction protein trafficking and cell growth. In 
these studies, specific occludin phosphosites and their role in barrier regulation and cell signaling 
have been identified [89, 90]. For example, phosphorylation of occludin at the threonine residues 
T403 and T404 by PKCη enhances TJ assembly and maintenance in epithelial cells [91]. In 
contrast, c-Src phosphorylation of occludin at the tyrosine residues Y398 and Y402 prevents its 
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association with ZO-1, leading to tight junction destabilization in epithelial cells [92]. In Caco-2 
cells, phosphorylation of occludin at residue S408 by kinase CK2 causes occludin-occludin 
interactions, disassociation of ZO-1, and an increase of small cation paracellular flux via 
claudins -1 and 2-based pores [93]. 
In retinal endothelial cells and an ischemia reperfusion model, the activation of the vascular 
endothelial growth factor receptor 2 (VEGFR2) by VEGF induces occludin phosphorylation at 
Ser490, and promotes ZO-1 and claudin-5 endocytosis and endothelial permeability [65]. 
Previous studies in BREC and in rats showed that S490 occludin phosphorylation by PKCβ leads 
to occludin ubiquitination, endocytosis and degradation, along with an increase in retinal 
endothelial permeability [74, 94]. Collectively, these studies reveal that post-translational 
modifications of occludin regulate barrier properties in retinal endothelial cells, through TJ 
protein endocytosis. The TJ protein occludin, while not required for junction assembly, appears 
to act as a regulator of barrier properties. 
Additionally, recent work revealed a role for occludin in cell growth regulation. Phospho-
specific antibodies detected a surprising population of occludin in centrosomes, along with an 
increase in Ser490 phosphorylation during mitosis [95, 96]. Mutation of Ser490 to alanine 
retarded MDCK cell growth and prevented both VEGF-induced proliferation and tube formation 
in cell culture and neovascularization in vivo [96]. A second phosphorylation site, located in the 
coiled-coil domain, also contributes to proliferation and tight junction formation. Recent studies 
reveal that MDCK epithelial cells undergo post-contact proliferation, which is necessary for 
proper epithelial maturation and tight junction formation. Inhibition of Ser471 phosphorylation 
by either an alanine mutation or inhibition of the G-protein regulated kinase that targets this site, 
prevents this epithelial maturation and blocks tight junction formation, with no effect on 
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adherens junction formation [97]. Together, these data show the complex role of occludin in 
barrier regulation, cell growth, angiogenesis, and permeability transport regulation.  
1.4.2.2 Tricellulin 
Tricellulin (MARVELD2) is a ~64kDa transmembrane protein localized at the tricellular 
contacts (TCs), region where the corners of three epithelial or endothelial cells meet [98, 99]. 
Like occludin, tricellulin has a long C-terminus tail but they only share about a 32% homology 
[100]. Interestingly, tricellulin-deficient mice as well as occludin-deficient mice develop hearing 
loss [100-102].   
A closer look at tricellulin organization in both cells and animals shows that loss of 
occludin alters tricellulin localization [101, 103]. In the absence or downregulation of occludin, 
tricellulin was observed to localize at bicellular tight junctions rather than at tricellular tight 
junctions. These results might suggest that in the absence of occludin, tricellulin can compensate 
for occludin in the formation of bicellular tight junctions. 
 Overexpression of tricellulin in fibroblasts shows that tricellulin is localized throughout 
the plasma membrane and does not concentrate at cell-cell contacts like claudins. However, 
when claudin-1 or -3 are overexpressed in fibroblasts tricellulin localize at cell-cell contacts 
[103]. These data indicate that claudins and occludin play a regulatory role in tricellulin’s 
organization at the tricellular tight junctions. Additionally, studies in epithelial cells show that 
the angulin family proteins comprised of angulin-1/lipolysis-stimulated lipoprotein receptor 
(LSR), angulin-2/immunoglobulin-like domain-containing receptor (ILDR1), and angulin-
3/ILDR2 recruit tricellulin to the TCs [104].  
While the majority of the studies on tricellulin have been in epithelial cells, work done by 
the Furuse lab revealed that tricellulin is present in the endothelial cells of the BBB and iBRB, 
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but not in other tissues composed of endothelial cells [99]. This observation suggests the 
importance of angulins and tricelllulin in the BBB and BRB.    
1.4.2.3 MARVELD3 
MARVELD3, the third member of the MARVEL family, is also a tetraspan protein but 
lacks the carboxyl tail found in occludin and tricellulin [105]. The role of MARVEL D3 in the 
BBB and BRB remains unclear. 
1.4.3 Junctional-Associated Adhesion Molecules (JAMs)  
JAMs are single-span proteins that belong to the immunoglobulin superfamily because 
they contain at least one IgG domain at their extracellular N-terminus [106, 107]. The 
cytoplasmic tails of JAMs contain a PDZ binding sequence that interacts with the PDZ domain 
of ZO-1. Like the second extracellular loop of claudins, the extracellular domain of JAMs can 
associate with JAMs from adjacent cells (trans-interaction) or in the same cell (cis-interactions) 
in a homophilic (same type of JAM) or heterophilic (different type of JAM) manner [108, 109]. 
In contrast to claudins, JAMs do not form tight junction strands, instead, they facilitate junctional 
assembly. 
JAMs are the first TJ proteins to appear during epithelial junction assembly. JAM-A co-
localizes with AF-6 and Par3 at the intercellular junctions of the RPE. Their expression in 
fibroblasts promotes ZO-1, AF6, and occludin localization at cell-cell contacts, leading to barrier 
formation [109, 110].  
In the cerebral and retinal endothelium, JAM-A is the predominant JAM isoform [111, 
112]. The exact role JAMs play in the regulation of paracellular barrier and transport of the BBB 
and BRB remain unclear; however, recent studies suggest a role of JAM in the movement of 
leukocytes through the wall of blood vessels, diapedesis. JAM-A expression on monocytes 
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facilitates its movement across the BBB [113], while JAM-A knockout and endothelial specific 
JAM-A deficient mice, exhibit impaired neutrophil transmigration [114]. Further, although JAM-
C and JAM-B are expressed at the junctions of the RPE, JAM-C deficient animals showed 
increased JAM-A expression and enhanced retinal vascularization [115, 116], suggesting a role 
for JAMs in retinal angiogenesis. 
Together, these data indicate that JAMs contribute to several mechanisms, including cell 
migration, immune cell infiltration and angiogenesis in the BBB and BRB. However, further 
studies are needed to determine the exact role of the different JAMs in the BBB and BRB 
formation and maintenance. 
1.4.4 Zonula Occludens (ZO)  
Zonula occludens (ZO) are large (>200 kDa) scaffold proteins that connect 
transmembrane proteins with the cytoskeleton and play an important role in tight junction 
organization. ZOs form part of the MAGUK family, and there are 3 isoforms: ZO-1, -2, and -3 
[78, 117, 118]. 
 ZO proteins contain three PDZ domains which allow the interaction between proteins 
that have a PDZ domain and the interaction for proteins with a PDZ binding motif domain like 
claudins and JAMs [56, 75, 119]. Further, occludin interacts with a Src homology 3, guanylate 
kinase GUK homology domain [76]. ZO proteins serve as links between the junctional 
complexes and the cytoskeleton by their ability to bind actin, α-catenin, and afadin (AF6) [120-
122], thus promoting TJ protein assembly at cell-cell contacts. 
ZOs play a critical role in tight junction formation. In the absence of all ZO isoforms, 
formation of TJs is impaired and claudins fail to polymerize, but no effects on the adherens 
junction are observed [123, 124]. Additionally, ZO-1 deficient mice are embryonic lethal and 
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express defects in the vasculature and neural tube development [125]. Several studies focusing 
on pathologies disrupting the BBB and the BRB have revealed that loss/reduction of ZO-1 
correlates with an increase in paracellular permeability [65, 126], thus supporting ZO-1 as a 
marker of leakiness of endothelial barriers. ZO-2 and ZO-3 are also expressed in BBB and BRB; 
however, their specific roles in endothelial barriers have not been addressed yet. 
1.4.5 Adherens Junctions (AJs)   
AJs play a critical role in cell-cell adhesion, cell polarity, contact inhibition, and 
paracellular transport regulation. The AJ of the iBRB includes vascular endothelial (VE)-
cadherin of the cadherin superfamily. VE-cadherin is a transmembrane Ca2+-dependent cell 
adhesion protein with a conserved cytoplasmic tail that binds to β-catenin. In vivo studies of 
transgenic mice deficient in VE-cadherin, which exhibit embryonic lethality by E9.5, have 
demonstrated that VE-cadherin is required for proper lumen formation and maintenance of newly 
formed vessels [127]. VE-Cadherin has an intimate relation to VEGF receptor and is a major 
control point for regulation of barrier development, paracellular permeability and growth control 
(for complete reviews, see: [47, 128, 129]). 
1.5 Pro-Barrier Mechanisms 
Maintenance and regulation of the vascular endothelial cell junctional complex is critical 
for normal barrier function of barriers of the CNS that help maintain a proper neuronal 
environment. Studies focusing on the mechanisms of barrier formation, maintenance, and 
disruption have been of particular interest to understanding development of the BBB and the 
BRB and identifying a means for therapeutic intervention for diseases ranging from brain tumors 
and dementia to blinding eye diseases. Research has revealed increasingly that small guanosine 
triphosphatases (GTPases) play a critical role both in barrier formation and disruption. Recent 
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studies have shed light on a direct role for small GTPases in barrier properties, assembly of 
adherens and tight junctions and prevention of barrier loss caused by permeabilizing agents such 
as inflammatory cytokines and growth factors. The discovery of the EPAC-Rap1 pathway has 
revealed a molecular mechanism by which cAMP signaling can promote barrier properties in the 
BBB and BRB and restore barrier properties after barrier breakdown.   
1.5.1 Small GTPases 
Small GTPases, like Rap1 and RhoA, have been identified as key regulators of both 
barrier formation and barrier disruption that promote signal transduction pathways that alter the 
junctional complex and regulate vascular permeability [130-132]. Small GTPases are hydrolase 
enzymes that bind and, over time, hydrolyze guanosine triphosphate (GTP) into guanosine 
diphosphate (GDP). These small GTPases serve as molecular switches that cycle between an 
active GTP-bound state and an inactive GDP-bound state. When in the GTP-bound form, 
GTPases undergo a conformational switch, which allows them to relay signals in the cell via 
interacting with and activating specific effector proteins [133]. Further, the activity of small 
GTPases is regulated by additional proteins, including guanine nucleotide exchange factors 
(GEFs) and GTPase-activating proteins (GAPs). GEFs promote signaling activity of small 
GTPases by facilitating the release of bound GDP, thereby allowing GTP to bind, while GAPs 
promote the hydrolysis of bound GTP, thus inactivating downstream signaling transduction. 
Additionally, guanosine nucleotide dissociation inhibitors (GDIs) regulate the activity of small 
GTPases by sequestering GDP-bound small GTPases in the cytoplasm and protecting them from 
degradation [134]. Small GTPases, including RhoA, Rac1, and Cdc42, can participate in both 
barriergenesis and barrier loss in response to a variety of extracellular cues and their 
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corresponding GEFs and GAPs. Recent research has helped to elucidate the role of small 
GTPases in barrier properties in the BBB and BRB. 
1.5.1.1 The Ras Superfamily of Small GTPases 
The Ras superfamily of small GTPases is composed of more than 154 proteins that are 
divided into the following 6 main families: Rheb, Ran, Arf, Rho, Ras, and Rab [135, 136]. Each 
GTPase family has a unique role in cell signaling. Broadly considering the Ras superfamily, the 
Ras homolog enriched in brain (Rheb) regulates the mTOR pathway. The Ras-like nuclear (Ran) 
GTPase family is the most abundant in the cell and is involved in nuclear transport of both RNA 
and proteins. The ADP-ribosylation factor (Arf) GTPase family contributes a role in vesicular 
transport. Further, the Ras-like proteins in the brain (Rab) GTPase family, like the Arf GTPases, 
regulate vesicle trafficking, including endocytosis and exocytosis. The Ras homologous (Rho) 
GTPase sub-family is involved in regulating cytoskeletal dynamics in cell shape and cell 
migration. The Ras sarcoma (Ras) GTPase family contributes to several cell signaling pathways 
such as transcription, cell differentiation, proliferation, and oncogenesis. For complete reviews, 
see refs [136-139].  
GTPases are involved in both endothelial barrier formation and disruption. Rho GTPase 
family members, such as Cdc42 and Rac1, promote endothelial barrier properties and are 
associated with downregulation of RhoA [132, 140, 141]. On the other hand, hyperactivation of 
RhoA and its downstream effectors, Rho-associated kinases (ROCK1 and ROCK2), and 
phosphorylation of myosin-regulatory light chain-2 (MLC2) are associated with endothelial 
barrier disruption [142-144]. Moreover, the Ras GTPase family member, Rap1 and its GEF, 
EPAC, are involved in several cellular adhesion mechanisms such as cell-cell adhesion and cell-
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extracellular matrix (ECM) adhesion [145]. Importantly, the interaction of EPAC1-Rap1 
signaling with endothelial specific rasip1 promotes endothelial barrier function [131, 146].   
1.5.1.2 Rho GTPases in Endothelial Barrier Regulation 
Rho GTPases are a family of small GTPases (~20 – 25kD) involved in regulating 
cytoskeletal dynamics. Three of these Rho GTPases are Cdc42 (Cell division control protein 42), 
Rac1 (Ras-related C3 botulinum toxin substrate 1), and RhoA (Ras homolog gene family 
member A) [147]. Broadly, Cdc42 promotes filopodia formation and Rac1 regulates lamellipodia 
formation, both protrusive actin-based structures, whereas RhoA regulates stress fiber formation 
and other actomyosin contractile arrays [148]. Each of these Rho GTPases is ubiquitously 
expressed and possesses distinct functions in the assembly and homeostasis of endothelial cell-
cell junctions, which are determined by tight spatiotemporal regulation of their activation state 
by GEFs and GAPs. 
Factors such as tumor necrosis factor alpha (TNF-α), thrombin, vascular endothelial 
growth factor (VEGF), and other vasoactive agents lead to activation of RhoA and there is broad 
consensus that RhoA activation contributes to barrier disruption [149, 150]. Activation of RhoA 
in endothelial cells causes the formation of stress fibers, which are associated with disruption of 
the inter-endothelial junctions, thus increasing paracellular flux (Figure 1.4.A) [151, 152]. Rho 
GTPases also regulate the inter-endothelial junctions that form barriers of the CNS. Retinas 
under ischemic conditions in diabetic retinopathy express elevated levels of VEGF, which 
contributes to retinal vascular permeability. Studies in retinal endothelial cells, show that VEGF 
induces activation of RhoA and its downstream effectors (Rho-associated kinases) ROCK1 and 
ROCK2 [153]. In vivo studies of diabetic rat models show hyperactivation of RhoA and 
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localization of RhoA and ROCK at the vascular retinal endothelial cells [154]. These data 
demonstrate the relevance of hyperactivation of RhoA in barrier disruption.  
However, RhoA has a dual role and has been reported to be important in AJ assembly 
[155]. Further, RhoA may contribute to both barrier loss and barrier induction dependent on the 
location of RhoA and the associated GEF. An elegant study using live imaging reveals that 
RhoA may contribute to TJ assembly associated with p114RhoGEF and TJ disassembly 
associated with GEF-H1 depending on the location of the RhoA being activated [156].  
Other members of the Rho GTPases also demonstrate dual roles in junction assembly and 
disassembly. Cdc42 and Rac1 have an important role in regulating the assembly of endothelial 
and epithelial cell junctions [157, 158]. Activation of Cdc42 promotes binding to IQGAP1, a 
scaffold protein that binds β-catenin and actin, leading to assembly of adherens junctions in cells 
[159-161]. However, in endothelial cells, some studies reveal that VEGF activation of Rac1 
promotes internalization of the vascular endothelial cadherin, VE-cadherin, leading to an 
increase in paracellular flux [162, 163].   
Together these data show the complexity and multifunctional roles that the Rho GTPases 
have in regulating the junctional complex and paracellular flux of endothelial cells, in both the 
peripheral vasculature and CNS barriers. Activation of RhoA may contribute to junction 
assembly based on the location of RhoA in the cell, and the specific GEF involved in its 
activation.   
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Figure 1.5 Small GTPases in Endothelial Barrier Regulation. Schematic, as seen from above, 
represents disorganized junctional complex versus organized junctional complex. A) Pro-inflammatory 
cytokines or growth factors bind and activate their corresponding GPCRs or RTKs and activate the 
RhoA/ROCK/pMLC signaling pathway which promotes formation of stress fibers and disrupts 
junctions causing an increase in paracellular permeability. B) Activation of EPAC via cAMP or cAMP 
analog activates Rap by promoting GTP exchange. Rasip1 localizes to the junctional complex by 
binging HEG1 and interacting with active Rap at the cell border. Rasip1 can dimerize via its RA domain 
and bind two Rap molecules at the plasma membrane. The active Rap-rasip1 complex and radil 
activates ArhGAP29, which inhibits RhoA activity and prevents loss of barrier. Downregulation of 
RhoA reduces stress fiber formation. Abbreviations: ROCK: Rho-associated kinases, pMLC: Phospho 
Myosin light chain, p120: catenin p120, ligand: can be pro-inflammatory cytokine or growth factor, GPCR: 
G-protein-coupled receptors, RTKs: Receptor Tyrosine Kinases, FHA: Forkhead-associated domain, 
HEG1: Heart of Glass 1, RA: Ras-associated domain, TJ: Tight Junctions, AJ: Adherens Junctions.  
(Figure from Ramos and Antonetti, 2017) 
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However, both inflammatory factors and growth factors regulate RhoA activity to promote 
breaks in the junctional complex and increase paracellular permeability. 
1.6 Cyclic AMP Second Messenger for Barrier Regulation 
The second messenger cyclic adenosine monophosphate (cAMP) plays an important role 
in multiple cell signaling pathways. Activation of G-protein-coupled receptors (GPCRs) leads to 
the activation of adenylyl cyclase which catalyzes ATP into cAMP. The effectors of cAMP 
include the classical protein kinase A (PKA) and cyclic nucleotide gated ion channels. In 1998, 
the Bos lab discovered an additional cAMP downstream target called exchange-protein-directly 
activated by cAMP (EPAC) that had a binding domain for the Rap1 small GTPase [164, 165].  
1.6.1 EPAC, a GEF for Rap  
The EPACs are guanine-nucleotide-exchange factors (GEFs), which activate Rap small 
GTPase proteins. Two isoforms of EPACs exist in mammals, the broadly expressed EPAC1 
(RapGEF3 in human), and EPAC2 (RapGEF4 in human), which is expressed in the brain, 
kidney, and pancreas (Figure 
 1.6.A) [145]. The EPACs are multidomain proteins consisting of a C-terminal catalytic 
region and an N-terminal regulatory region [166]. The C-terminal catalytic region contains the 
following domains: the cell division cycle 25 (CDC25), homology domain (CDC25HD) which 
has the GEF activity specific for Rap; a protein interaction motif called Ras-associated (RA) 
domain; and a Ras exchange motif (REM), which is a region found in Ras and Rap GEFs 
involved in stabilization of the active GEF conformation [167]. The N-terminal regulatory region 
contains a Dishevelled, Egl-10, Pleckstrin (DEP) domain, which is involved in membrane 
attachment and the cyclic-nucleotide-binding (CNB) domain to which cAMP binds [164]. 
EPAC2 has an additional cAMP-binding domain, CNB, on its N-terminus [168]. EPACs have a 
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cAMP-binding site similar in sequence to the cAMP-binding domain from PKA and are also 
activated by cAMP [164]. When cAMP binds to the EPAC regulatory region, it allows the auto-
inhibitory inactive state to change to an active state and bind to the small GTPases in the Rap 
family (Figure 1.6.B). Once EPAC is bound to Rap, it can exchange GDP for GTP, thus 
activating the Rap proteins (Figure 1.6.C) [169].  
Gene deletion studies revealed a role for EPAC in mouse metabolism and behavior.  
Interestingly, in vivo studies show that global EPAC1 knockout is not lethal; however, the global 
EPAC knockout mice express a variety of phenotypes. Kai et al. show that the EPAC1 null mice 
have B-cell dysfunction, impaired glucose tolerance, obesity, and insulin resistance [170]. On the 
contrary, Yan et al. show that their EPAC1 null mice are resistant to high-fat diet-induced 
obesity, hyperleptinemia, and glucose intolerant [171]. In a 2012 study, EPAC1 and EPAC2 null 
animals were generated, as well as double knockout EPAC1/2 mice [172]. In the animals with a 
single isoform EPAC1 or EPAC2 gene deletion, no abnormalities were observed; however, in 
the double knockout mice, severe deficits of spatial learning and social interactions were 
observed.  
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Figure 1.6 EPAC Structure and Activation via cAMP. A) Rap proteins are GTPases that 
hydrolyze GTP into GDP. GAPs increase the rate of GTP hydrolysis leading to GDP bound 
Rap, the inactive state. On the other hand, GEFs, such as EPAC, facilitate the exchange of GDP 
for GTP promoting the GTP bound Rap, the active state. B) EPAC has two known isoform 
proteins, EPAC1 and EPAC2, encoded in separate human genes, RAPGEF3 on chromosome 12 
and RAPGEF4 on chromosome 2, respectively. EPAC’s catalytic region contains the CDC25-
HD, RA, and REM domains. The regulatory region contains the CNB and DEP domains. The 
EPAC2 protein contains an additional CNB region. C) EPAC exists in an autoinhibitory 
inactive state with the regulatory region suppressing the guanine nucleotide exchange (GEF) 
function of the catalytic region. The binding of cAMP to the CNB domain, located in the 
regulatory region, promotes a conformational change from an inactive to an activate state. The 
active EPAC binds Rap GTPases and facilitates the exchange between GDP to GTP. 
Abbreviations: EPAC: exchange factor directly activated by cAMP, GAP: GTPase-activating 
proteins, GEF: guanine nucleotide exchange factors, RAPGEF: Rap guanine nucleotide exchange 
factor, CDC25-HD: cell division cycle 25 homology domain, RA: Ras-associated domain, REM: 
Ras exchange motif, DEP: Disheveled, Egl-10, and Pleckstrin domain, CNB: cyclic nucleotide-
binding domain. (Figure from Ramos and Antonetti, 2017) 
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1.6.2 The Role of Rap1 in Endothelial Cell Barrier 
The Ras-related protein 1 (Rap1) is a small GTPase in the Ras family, known for its role 
in cell adhesion and cell junction regulation. Vertebrates express two highly homologous Rap1 
isoform proteins, Rap1a and Rap1b, which are encoded by different genes [173]. Additionally, 
they express Rap2, which has approximately a 60% sequence homology to Rap1 [174, 175]. 
Rap2 has three isoforms (Rap2a, Rap2b, and Rap2c) and their distinct functions have not been 
well studied [176]. Rap1 activation is regulated by several Rap1-specific GEFs. These are CD-
GEF1, C3G, PDZ-GEF1, and the EPACs discussed above [136, 177].   
Rap1 gene deletion studies reveal that Rap contributes to a number of cell functions in 
vascular endothelial cells, including vasculogenesis and angiogenesis. Rap1 promotes VEGF 
receptor (VEGFR2) activation and is required for angiogenesis by a mechanism involving the 
integrin αvβ3 [178]. Rap1a and b isoforms can compensate for one another but recent work has 
also shown that the isoforms have distinct functions [179-181]. To study the differences of the 
Rap1 isoforms, mouse knockouts of each Rap1 isoform were generated. Mice with Rap1a 
knockout are viable and have no size difference in comparison to wild type mice. These animals 
exhibited defective leukocyte adhesion, altered myeloid cell function, and partial embryonic 
lethality [179, 182].  
Global Rap1b knockout in mice leads to about 80% embryonic lethality between 
embryonic (E) day 13.5 and 18.5. This suggests that Rap1b is not necessary for vasculogenesis, 
which occurs from E7.5 to E10.0, but rather, it is necessary for further maturation of the 
vasculature [183]. Post-mortem analysis revealed that Rap1b null mice manifested abdominal, 
vascular and cranial hemorrhage due to a platelet defect. The Rap1b viable mice were smaller in 
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size and exhibited prolonged bleedings during tail bleeds [184]. Further studies of the Rap1b null 
mice identified defective angiogenesis, which led to a retardation in retinal neovascularization. 
Additionally, lung endothelial cells from the Rap1b null mice demonstrated defective endothelial 
migration and proliferation, due to impaired MAPK signaling. The lung endothelial cells from 
Rap1b null mice have a decreased response to growth factors VEGF and basic fibroblast growth 
factor (bFGF) [180].  
Double Rap1a and Rap1b knockout leads to complete embryonic lethality by E10.5. The 
endothelial and hemangioblast specific double Rap1a and b knockout achieved by expression of 
Cre under Tie2 is completely lethal by E15.5. These animals expressed a leaky vasculature and 
engorged perineural vessels [181]. Interestingly, mice are viable with at least one allele of Rap1b 
but not with just one allele of Rap1a. These data together suggest that the Rap proteins are not 
required for early gastrulation development but are required for further development of the 
embryo. The data also suggest that Rap1b contributes a critical role in endothelial vasculature in 
comparison to Rap1a.  
1.6.3 EPAC-Rap1 Signaling Pathway in Endothelial Cell Barrier Induction 
Investigations on the cellular role of the EPAC-Rap1 signaling pathway have been 
facilitated by the development of cAMP analogs specific for EPAC, allowing for discrimination 
between PKA-independent cellular mechanisms and EPAC-dependent mechanisms. Popular 
EPAC selective cyclic AMP analogs used in cell culture and in vivo are 8-(4-chloro-phenylthio)-
2´-O-methyladenosine-3´,5´-cyclic monophosphate (8-pCPT-2´-O-Me-cAMP) and the improved 
membrane permeable 8-pCPT-2´-O-Me-cAMP-AM, which contains an acetoxymethyl group 
(AM) to mask the negative charge from the phosphate group [185, 186]. These studies have 
elucidated the role of EPAC in integrin-mediated cell adhesion, E-cadherin-mediated cell 
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adhesion, and cell signaling. Studies performed using human umbilical vein endothelial cells 
(HUVEC) show that EPAC activation leads to the recruitment of VE-cadherin to the cell border 
and formation of long, linear and continuous adherens junctions [187]. This VE-cadherin-
mediated junctional organization in HUVEC results in a decrease in solute flux [188]. Additional 
observations of EPAC activation included reduction of stress fiber formation and defined cortical 
actin at the cell periphery. Interestingly, actin rearrangements after EPAC activation are not VE-
cadherin mediated [188, 189].  
Activation of EPAC in endothelial cells requires Rap activity for barrier induction. 
Addition of 8-pCPT-2´-O-Me-cAMP for EPAC stimulation leads to activation of Rap1 
associated with enhanced endothelial barrier properties and induces a continuous and linear 
distribution of VE-cadherin in both HUVEC and rat mesenteric vessels [189, 190]. The effect of 
EPAC activation on barrier properties requires Rap1 activity as silencing of Rap1 in HUVEC 
blocked 8-pCPT-2´-O-Me-cAMP-induced barrier function, as measured by trans electrical 
resistance [191]. Cullere et al. revealed that Rap1 localizes at the cell-cell junctions and 
inhibition of endogenous Rap1 disrupts the junctional complex [187]. Additionally, afadin (AF-
6), a scaffold protein that binds to actin filaments and adhesion proteins, localizes at the cell 
periphery after EPAC activation and may serve as a molecular link between EPAC/Rap1 and the 
junctional complex [192, 193].  
The EPAC-Rap1 pathway can prevent the action of permeabilizing agents on vascular 
endothelial cells. Activation of EPAC blocks thrombin-induced permeability by down regulating 
RhoA activity [187]. In HUVEC, EPAC1 activation reverses the transendothelial resistance 
decrease caused by both TNF-α and the transforming growth factor (TGF-β). Additionally, 
knockdown of EPAC1 alone induced a decrease in transendothelial resistance [194]. Moreover, 
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in vivo studies of the mesenteric microvasculature show that activation of the EPAC-Rap1 
pathway via 8-pCPT-2´-O-Me-cAMP attenuates platelet-activating factor (PAF)-induced 
permeability as well as prevents PAF-induced VE-cadherin disorganization [190]. 
1.6.4 Active Rap1 Binds to Rasip1 in Endothelial Cells 
In 2004, Mitin and colleagues identified ras-interacting protein 1 (rasip1) as a potential 
effector of Ras through a yeast two-hybrid screen. They showed that rasip1 contains a Ras-
associating (RA) domain at the N terminus, which has a high sequence homology to AF-6, a 
known Ras/Rap effector as well as a scaffold intermediate protein that links the cytoskeleton to 
cell-cell junctions [195]. Additionally, rasip1 possesses a proline rich region like the Src 
homology 3 (SH3) domain binding motifs and a dilute (DIL) domain which is found in myosin V 
proteins involved in cargo loading during vesicle trafficking [195, 196]. Rasip1 expression is 
restricted to the vascular endothelium [197]. Rasip1 was identified as an endothelial-specific 
gene in an endothelial cell-specific transcriptome analysis of publicly available microarrays 
[198] and both whole mount embryo in situ hybridization and immunofluorescence reveals 
Rasip1 expression is restricted to the vascular endothelium [131, 199].   
Xu et al. performed in vivo studies showing that rasip1 is restricted to the vascular 
endothelial cells of both mice and frogs and has an important role in vasculogenesis and 
angiogenesis. In mice, rasip1 is first observed at E7.0 in the parietal yolk sac and its expression is 
observed all the way until adulthood, implying that rasip1 is important in vasculogenesis and 
vessel maintenance [199]. Moreover, rasip1 interaction with GTPases in peripheral vessel 
endothelial cells regulates tubulogenesis and lumen formation. In this study, rasip1 null mice 
failed to form lumens in all blood vessels and were embryonic lethal at E10.5 displaying growth 
retardation, hemorrhage, and widespread edema [197]. Confocal microscopy of angioblasts 
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showed disruption in cell polarity due to mislocalization of Par3 and failure of junctional protein 
localization at the cord periphery. Additionally, Xu and colleagues showed that rasip1 and Rho 
GTPase-activating protein 29 (ArhGAP29) regulate endothelial cell architecture and tube 
formation. Endothelial cells depleted of either rasip1 or ArhGAP29 show increased activity of 
RhoA/ROCK/myosin II and decreased Cdc42 and Rac1 activity [197]. This was the first 
observation describing rasip1 as a downregulator of Rho signaling. Recently, rasip1 conditional 
gene deletion at different developmental time points [200] showed that rasip1 is essential for 
vessel formation and maintenance at different embryonic time points. Additionally, rasip1 is 
required for angiogenesis. Retinas of rasip1 null mice at P6 show a decrease in vessel growth, 
impaired lumen formation, and poorly organized capillary plexus [200].  
An important contribution in understanding the function of rasip1 in endothelial cells was 
the identification of rasip1 as a Rap1-effector involved in endothelial barrier properties [146]. 
Activation of EPAC activates Rap1, and active Rap1 interacts with rasip1. Rasip1, together with 
ras-associated and dilute domain-containing protein (radil), recruit ArhGAP29, which in turn 
downregulates RhoA activity (Figure 1.4.B) [146]. Wilson et al, revealed that rasip1 mediates 
vascular endothelial junction stability through EPAC1-Rap1 signaling in vivo. Rasip1 null mice 
demonstrate embryonic lethality at E10.5 and the embryos displayed collapsed vessels, 
multifocal hemorrhage, edema, and smaller vessels [201]. One unique observation Wilson and 
colleagues made was that rasip1 null mice formed primitive vessel tubes that allowed the 
circulation of erythrocytes, but due to impaired cell-cell adhesion, these early vessels collapsed. 
They also observed no difference in cell motility between rasip1-deficient endothelial cells and 
controls.  
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HUVEC siRNA experiments further support a role of rasip1 in regulating vascular 
permeability. Additionally, rasip1 localizes at the cell borders, promotes cortical actin assembly, 
and interacts with Rap1 in an EPAC1-dependent manner. Knockdown of either Rap1 or EPAC1 
in HUVEC prevents rasip1 localization at the cell borders and knockdown of either rasip1, 
EPAC1, or Rap1 leads to disorganization of F-actin at the periphery of cells. Together these data 
provide strong evidence for the role of EPAC1-Rap1-rasip1 signaling in regulating endothelial 
permeability. 
Rasip1 transiently localizes to endothelial cell-cell junctions in a Rap-mediated manner 
[201]. A recent study showed that the localization of rasip1 to the endothelial cell-cell junctions 
occurs by anchoring to Heart of Glass 1 (HEG1), a transmembrane receptor involved in 
cardiovascular development [202]. Silencing HEG1 reveals that HEG1 is required for rasip1 
localization at cell junctions. Mutational studies identified 9 amino acids (aa) from 1327-1335 in 
HEG1 that bind to rasip1 at the Forkhead-associate domain (FHA), aa 266 – 550. Deletion or 
mutations in FHA or HEG1’s 9 aa region inhibits the interaction between rasip1 and HEG1 and 
prevents rasip1 inhibition of Rho signaling [202]. Furthermore, HEG1 knockdown, like rasip1 
knockdown, shows an increase in Rho signaling activity and HEG1 rescue assays inhibit Rho 
signaling. These data suggest that HEG1 facilitates the translocation of rasip1 to cell junctions 
where it can bind to active Rap1 and downregulate Rho signaling (Figure 1.4.B).  
Protein crystallography studies and modeling suggest that rasip1 forms a dimer and each 
Ras-associated (RA) domain can bind to one molecule of either Rap or Ras [203]. Therefore, a 
rasip1 dimer could bind to two Rap proteins (Figure 1.4.B) [203]. An interesting concept by 
Rehmann and Bos suggests that rasip1 and radil could potentially dimerize with each other since 
both proteins show a 30% sequence homology in the their RA domain [202, 204]. They propose 
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that the potential dimerization between rasip1 and radil could explain how ArhGAP29 is 
recruited since both radil and ArhGAP29 possess a PDZ domain and previous studies have 
shown coimmunoprecipitation of radil and ArhGAP29 [205].  
1.7 Objectives  
It is clear from the studies described above that the small GTPase, Rap1, and the GEF, 
EPAC, contribute to barrier properties in endothelial cells. However, the role of the EPAC-Rap1 
signaling pathway in barriers of the CNS has not been examined in detail. The goal of this thesis 
is to investigate the ability of the EPAC-Rap1 signaling pathway to restore barrier properties and 
block permeability induced by permeabilizing agents, as well as to identify novel targets 
downstream of VEGF signaling. Therapeutically targeting small GTPases may yield specific 
opportunities to restore barrier properties of the BBB and BRB, preventing or limiting disease 
pathology for a host of diseases that involve brain or retinal edema.  This dissertation contains 
two data chapters, followed by a conclusion and future directions chapter. The content of each 
data chapter is briefly outlined below. 
Chapter 2: EPAC-Rap1 Signaling Restores the Blood-Retinal Barrier after Vascular Endothelial 
Growth Factor 
In this chapter, the hypothesis that activation of the EPAC-Rap1 signaling pathway 
antagonizes VEGF signaling and restores barrier properties in retinal vascular endothelial cells is 
addressed. Here, I demonstrate that activation of EPAC via the cAMP analog 8-pCPT-2´-O-Me-
cAMP-AM can block, and importantly reverse, VEGF and TNF-α-induced permeability in 
retinal endothelial cells and in vivo in the retina. Silencing of the Rap1b isoform induces an 
increase in basal endothelial cell permeability. Further, VEGF does not have an additive increase 
in permeability, suggesting that VEGF signaling may act, in part, through inhibition of the Rap1 
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pathway. Immunofluorescence staining of tight junctions (ZO-1, occludin, and claudin-5) shows 
that activation of EPAC prevents the VEGF-induction of tight junction barrier disorganization 
that is associated with VEGF-induced permeability. The combined in vitro and in vivo data 
suggest that EPAC-Rap1 signaling plays an important role in regulating endothelial paracellular 
flux by recruiting, organizing, and stabilizing the inter-endothelial adherens junctions and tight 
junctions.  
Chapter 3:  Elucidating the molecular mechanism of aPKC regulation of VEGF-induced retinal 
vascular endothelial permeability 
In this chapter, I address the hypothesis that VEGF regulates retinal endothelial 
permeability at least in part via protein phosphorylation changes downstream of aPKC. Mass 
spectrometry-based phosphoproteomics were utilized to analyze phosphorylation changes 
induced by VEGF and reversed by an aPKC inhibitor. In these studies, 1,724 proteins were 
identified and of these 107 phosphoproteins showed a 25% phosphorylation change and were 
repeated in more than one mass spectrometry analysis. Bioinformatics analysis of the 107 
phosphoproteins identified a protein-protein interactive subnetwork consisting of EPAC, rasip1, 
and Rap1. 
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CHAPTER 2 
EPAC-Rap1 Signaling in Blood-Retinal Barrier Maintenance and Restoration* 
 
2.1 Abstract 
Increased retinal vascular permeability contributes to macular edema, a leading cause of 
vision loss in eye pathologies such as diabetic retinopathy (DR), age-related macular 
degeneration (AMD), and central retinal vein occlusions. Pathological changes in vascular 
permeability are driven by growth factors such as vascular endothelial growth factor (VEGF) and 
pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α). Understanding pro-barrier 
mechanisms that block vascular permeability and restore the blood-retinal barrier (BRB) may 
lead to novel therapies. The cAMP-dependent guanine nucleotide exchange factor, EPAC, 
promotes exchange of GTP of the small GTPase, Rap1. Rap1 enhances barrier properties in 
human umbilical endothelial cells by recruiting Rasip1, which inhibits RhoA and promotes 
adherens junction assembly. In this study, we hypothesized that the EPAC-Rap1 signaling 
pathway regulates the tight junction complex of the blood-retinal barrier and can restore barrier 
properties after cytokine induced permeability. Here, we show that stimulating EPAC or Rap1 
activation can prevent and reverse VEGF and/or TNF-α induced permeability in cell culture and 
in vivo.  
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In addition, activation of EPAC inhibits VEGF receptor (VEGFR) signaling through the 
Ras/MEK/Erk pathway. We show that Rap1B knockdown or an antagonist for EPAC increases 
endothelial permeability and VEGF has no additive effect, suggesting a common pathway. 
Additionally, GTP-bound Rap1 promotes tight junction assembly and loss of Rap1B leads to loss 
of junctional border organization. Collectively, our results indicate that the EPAC-Rap1 pathway 
helps maintain basal barrier properties in the retinal vascular endothelium, and activation of the 
EPAC-Rap1 pathway represents a potential therapeutic strategy to restore the BRB. 
2.2 Introduction 
The retinal vasculature provides oxygen and nutrients to the inner retina and forms the 
inner blood-retinal barrier (iBRB) that helps maintain the retinal environment, allowing for 
proper neural function [25]. The BRB maintains strict regulation of vascular permeability 
through a continuous endothelium lacking fenestrations,  has limited transcellular vesicles, and 
controls the flux through the intercellular spaces between endothelial cells through the formation 
of a well-developed junctional complex [41, 42].  
Tight junctions (TJs) promote endothelial cell barrier properties by restricting the passage 
of molecules through the intercellular space (gate function) and conferring cell polarity by 
preventing lateral diffusion of lipids and proteins in the plasma membrane (fence function) [35]. 
Over 40 proteins make up the TJs that are subdivided into transmembrane and scaffolding 
proteins [129]. Important retinal endothelial cell transmembrane proteins include, but are not 
limited to, occludin and claudin-5 along with scaffolding proteins zonulae occludentes such as 
ZO-1, 2 and 3, which connect the TJ to the actin cytoskeleton. Eye pathologies that result from 
*Note: This chapter has been submitted to JBC for publication and it is currently under review.  
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elevated levels of permeabilizing agents such as vascular endothelial growth factor (VEGF) and 
pro-inflammatory cytokines like TNF-α exhibit increased retinal vascular permeability, which 
occurs at least in part by disrupting TJ organization [23]. TJ disruption may be mediated by 
VEGF-induced occludin phosphorylation [89], or TNF-α-induced reduction in claudin-5 and ZO-
1 expression [206] as well as currently uncharacterized mechanisms. Current medical therapies 
for macular edema involve intraocular injection of anti-VEGF agents, which demonstrate good 
effectiveness in approximately half of treated patients [207]. 
The second messenger 3´, 5´-cyclic adenosine monophosphate (cAMP) regulates several 
cell signaling pathways including barrier properties in endothelial cells [208, 209]. In addition to 
the well-studied cAMP effector protein kinase A (PKA) an additional cAMP effector was 
identified, named exchange-protein-directly activated by cAMP (EPAC) [164]. This exchange 
factor targets the small GTPase, Ras-associated protein (Rap), promoting exchange of GDP for 
GTP and activation of Rap [210]. Mammals express two isoforms of the EPAC protein, EPAC1 
(RapGEF3), which is widely expressed, and EPAC2 (RapGEF4), which is prominently 
expressed in the brain and adrenal gland [211]. The Rap proteins are small GTPases in the Ras 
family involved in several cell-signaling mechanisms. Mammals express two Rap proteins from 
separate genes, Rap1 and Rap2, which share approximately 60% protein sequence homology 
[174, 175]. Rap1 is further divided into two highly homologous isoforms, Rap1A and Rap1B, 
which are encoded by different genes [173]. Rap2 has three isoforms (Rap2A, Rap2B, and 
Rap2C) and their functions have not been well characterized [176]. Vascular development 
requires Rap1 proteins, as vasculature conditional gene deletion of both Rap1A and Rap1B leads 
to complete embryonic lethality by E15.5 [181]. Interestingly, mice with Rap1A deleted and only 
one Rap1B allele are viable, whereas mice with Rap1B deleted and only one Rap1A allele are 
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not, suggesting a critical role for Rap1B in endothelial vasculature [181]. Active Rap1 proteins 
are known for their role in cell adhesion in leukocytes [184] and cell adherens junction 
regulation [212]. However, the relation of Rap to TJs is not well understood.  
The development of EPAC-specific cAMP analogs, such as 8-(4-chloro-phenylthio)-2´-
O-methyladenosine-3´,5´-cyclic monophosphate (8-CPT-2′-O-Me-cAMP) and the improved 
membrane permeable 8-pCPT-2´-O-Me-cAMP-AM (8CPT-AM), which contains an 
acetoxymethyl group (AM) to mask the negative charge from the phosphate group, has allowed 
investigation of the cAMP-EPAC-Rap1 pathway independent of PKA signaling. Studies 
focusing on the activation of EPAC-Rap1 signaling in endothelial cells such as human umbilical 
vein endothelial cells (HUVEC) have identified a role for EPAC/Rap in regulating barrier 
properties through cortical actin increase at the endothelial junctions [189], recruitment of 
junctional proteins such as VE-cadherin [213], and inhibition of the small GTPase, RhoA, known 
to be involved in permeability [187]. More recently it has been demonstrated that the interaction 
of Rap1 with the endothelial-specific effector, ras-interacting protein 1 (rasip1), promotes 
endothelial barrier function by recruiting Rho GTPase-activating protein 29, ArhGAP29, 
downregulating the activity of RhoA [146, 201]. However, very little is known about the role of 
the EPAC-Rap1 signaling pathway in endothelial cells that form barriers of the CNS such as the 
BRB.  
In the present study, we demonstrate a role for EPAC-Rap1 signaling pathway in retinal 
vascular endothelial cells. We show Rap1B confers basal barrier properties to retinal endothelial 
cells and that pharmacologic activation of the EPAC-Rap1 pathway can prevent and restore BRB 
properties after both growth factor- and inflammatory factor-induced permeability. Further, 
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activation of EPAC-Rap1 signaling is shown to promote TJ organization and reduce paracellular 
permeability. 
2.3 Methods 
2.3.1 Reagents: The following reagents were purchased from Tocris Bioscience: the cAMP 
analog 8-pCPT-2-O-Me-cAMP-AM (8CPT-AM) specific for EPAC (catalog #4853), EPAC2 
inhibitor (HJC 0350) 2,4-Dimethyl-1-[(2,4,6-trimethylphenyl) sulfonyl]-1H-pyrrole (catalog 
#4844), and EPAC inhibitor (ESI 09) α-[(2-(3-Chlorophenyl) hydrazinylidene]-5-(1,1-
dimethylethyl)-β-oxo-3-isoxazolepropanenitrile (catalog #4773). Recombinant human VEGF165 
was from R&D Systems (Minneapolis, MN).  
2.3.2 Antibodies (Ab): The following antibodies were used for western blotting. Purchased from 
Cell Signaling: AKT rabbit polyclonal (pAb) (catalog #9272), phospho-AKT (Ser473) rabbit 
monoclonal (mAb) (catalog #4060), phospho-CREB (Ser133) rabbit mAb (catalog #9198). 
CREB rabbit mAb (catalog #9197), VEGFR2 rabbit mAb (catalog #2479), phospho-VEGFR2 
(Tyr1175) rabbit mAb (catalog #3770), Erk1/2 rabbit pAb (catalog #9102), phospho-Erk1/2 
(T202/Y204) mouse (catalog #9106L) and β-actin mouse mAb (catalog #3700). EPAC rabbit 
pAb (catalog #sc-25632) was purchased from Santa Cruz Biotechnology (SCBT) (Santa Cruz, 
CA, USA). The following were used in tissue and cell staining: Rap1A mouse mAb (catalog #sc-
373968) SCBT, CA, IB4, Hoescht. ZO-1 rat (catalog #MABT11, Millipore, USA), Claudin-5 
rabbit (catalog #34-1600, Invitrogen, USA), and Occludin mouse 488 Alexa (catalog #331588, 
Lifetech, USA). 
2.3.3 In vivo Permeability Assays: For the Evans Blue permeability assay, male Long-Evans 
rats (Charles River Laboratories, Wilmington, MA, USA) weighing 200g-250g were housed in 
accordance with the guidelines of the institutional animal care and use committee (IACUC) and 
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consistent with ARVO Statement for the Use of Animals in Ophthalmic and Visual Research. 
The IACUC approved all animal procedures. Rats were anaesthetized with intramuscular 
injection of ketamine and xylazine (66.7 mg/kg and 6.7 mg/kg of body weight, respectively). A 
32-gauge needle was used to create a hole for an intravitreal injection (2 μL/eye) using a 5 μl 
Hamilton syringe. The experimental animal groups received an intravitreal injection of VEGF 
(50ng) and TNF-α (10ng) together, or VEGF/TNF-α/8CPT-AM either at 10μM (355ng) or 
50μM (1.78µg) simultaneously. The animals recovered for 3 hours and were then anaesthetized 
again for the permeability assay as described by our group previously [214]. For studies using 
ischemia reperfusion to induce vascular permeability and retinal sterile inflammatory response, 
mice underwent ischemia on their left retina by increasing the intraocular pressure in the anterior 
chamber with PBS in order to block the blood supply from the retinal artery for 90 min followed 
by natural reperfusion, as described previously [65]. 
2.3.4 Solute Flux Assay: Primary bovine retinal endothelial cells (BREC) were isolated and 
grown in culture as previously described [215] to model the vascular endothelial blood-retinal 
barrier in vitro [216]. BREC were seeded on 0.4 μm pore transwells filters (Corning Costar, 
Acton, MA, USA) coated with 1µg/cm2 fibronectin. BREC were grown to confluence in MCDB-
131 medium, supplemented with 10% fetal bovine serum (FBS), 22.5µg/mL endothelial cell 
growth factor, 120µg/mL heparin, 0.01mL/mL antibiotic/antimycotic. Then cell culture media 
was changed to stepdown media, MCDB-131 supplemented with 1% FBS, 0.01 mL/mL 
antibiotic/antimycotic, and 100 nmol/L hydrocortisone, for 48 hours prior to experiment. For 
experiments with TNF-α treatment, no hydrocortisone was in the stepdown media. The cells 
were treated with VEGF (50ng/mL) for 30 minutes, and/or with TNF-α (10ng/mL) or 8CPT-AM 
(1µM unless otherwise stated) for indicated time. Cell monolayer permeability to 70 kDa 
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rhodamine isothiocyanate (RITC) dextran (Sigma-Aldrich Corp., St. Louis, MO, USA) was 
calculated by measuring the rate of flux of the substrate over a 4 hour time course followed by 
calculating the diffusive permeability (Po) across the monolayer [28]. 
Po = [(FL/Δt)VA]/(FAA) 
Where Po is in cm/s, FL is basolateral fluorescence, FA is apical fluorescence, Δt is the change in 
time, A is the surface area of the filter and VA is the volume of the basolateral chamber.   
2.3.5 Transendothelial Electrical Resistance (TEER) Assay: Cell monolayer ion flux was 
measured by electrical resistance using an electrical cell-substrate impedance sensing (ECIS)-Zϴ 
system at 4000 Hz (Applied Biophysics, Troy, NY). BRECs were seeded on 8-wells 8W10E+ 
ECIS plates containing gold electrodes. Cells were left to grow overnight or until 90% confluent 
followed by media changed to stepdown media for 48 hours. After 48 hours of stepdown the 
monolayers of cells were treated with compounds of interest.  
2.3.6 GTP Bound Rap1 Pull-down and Detection Assay: Pull-down for active Rap1 based on 
capture using the GST linked peptide of the downstream Rap1 effector Ral guanine nucleotide 
dissociation stimulator (RalGDS) Rho binding domain (RBD) kit was purchased from (Thermo 
Scientific, Rockford, IL, USA) (kit cat #16120) and used per manufacturer instructions. Cells 
were lysed with 500 µL of 1X lysis/binding/wash buffer provided in kit, centrifuged at 16,000 x 
g for 15 minutes at 4○C and supernatant was transferred onto spin cup collection tube containing 
Glutathione Resin. GST-RalGDS-Rap binding domain (RBD) fusion protein (20 µg/spin cup) 
was added to the supernatant and incubated for 1 hour with gentle rocking at 4○C. Samples were 
then centrifuged at 6,000 x g for 30 seconds, washed 3 times, and eluted with 50 µL of 2X 
reducing sample buffer (1-part β-mercaptoethanol to 20 parts 2X SDS Sample Buffer; Thermo 
Scientific, Rockford, IL, USA). Eluted samples, 25 µL, and total cell lysates, 30µg, were loaded 
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onto NuPAGE SDS gels for western blot analysis. Captured GTP-bound Rap1, as well as total 
Rap1 protein in lysate was detected using the anti-Rap1 rabbit mAb provided by the GTP-Rap1 
Pull-down kit (Thermo Scientific).       
2.3.7 Immunofluorescent (IF) Staining: For IF staining and imaging, BREC were fixed with 
1% paraformaldehyde for 10 minutes at room temperature (RT). The cells were permeabilized 
with 0.2% Triton X-100 followed by blocking with 10% milk in 0.1% Triton X-100 for 1 hour at 
RT. Cells were stained with primary antibodies for 2 days at 4○C. Cells were washed, then 
stained with secondary antibodies overnight at 4○C. Cells were imaged with Leica confocal 
microscope (TCS SP5; Wetzlar, Germany).  
2.3.8 Western Blot: Cell lysates, 30µg of protein, were loaded into each well of NuPAGE SDS 
gels (Life Technologies, Carlsbad, CA) and separated by electrophoresis. After nitrocellulose 
membrane transfer, membranes were blocked in 2% ECL Prime Blocking Reagent and incubated 
with primary antibodies overnight at 4○C. Secondary antibodies IgG conjugated with HRP were 
detected with Lumigen ECL ultra chemiluminescent reagent (Lumigen, Inc, TMA-100; 
Southfield, MI, USA).   
2.3.9 Viability Assay: To measure viability of cells, the CellTiter-Fluor Cell Viability assay was 
used according to manufacturer’s protocol (Promega, Madison, WI, USA). The fluorescent 
signal proportional to the number of living cells is generated by the cell-permeant peptide 
substrate (glycyl-phenylalanyl-aminofluorocoumarin; GF-AFC) which is cleaved by live cell 
protease activity. Cells were grown on 96-well plate until they reached confluency and then 
changed to step down media for 48 hours. VEGF (50ng/mL), DMSO (50%), ESI 09, HJC 0350, 
or vehicle were diluted in media, applied to the cells at a final volume of 100µL and incubated 
for 1 hour. The CellTiter-Fluor Reagent was added in an equal volume, mixed briefly using 
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orbital shaker, and incubated for 30 minutes at 37○C. Fluorescence was measured after 1.5 hours 
using a fluorometer (355nmEx/520nmEm).  
2.3.10 Gene Expression Knockdown Experiments: Composite and individual Rap1B siRNAs 
specific for bovine (sc-270595, sc-270595A (Rap1B-1 siRNA), sc-270595B, and sc-270595C; 
Santa Cruz, CA, USA) were purchased from SCBT. BRECs were transiently transfected with 
100nM of either Rap1B siRNA or scramble siRNA (siGENOME Non-Targeting siRNA#1, D-
001210-01-05; Dharmacon GE Healthcare, USA) using the nucleofection technique (Lonza). 
Briefly, cells were trypsinized and 5x105 cells were used per nucleofection. Nucleofection 
solution and supplement solution were used to resuspend the cell pellet in a final volume 100µL. 
The cell suspension was mixed with 100nM of siRNAs in cuvette and nucleofection carried out 
per manufacturer instructions (setting S-05; Amaxa Biosystems). Cell were diluted with 0.5 mL 
MCDB-131 media and added onto 6-well plates containing 1.5mL of media. Nucleofected cells 
were gently mixed in a total of 2 mL media then 0.5 mL of cell suspension were plated directly 
onto fibronectin-coated 0.4 μm pore transwell filters. After 4 hours, the media was replaced with 
fresh MCDB-131 media. Confluent cells were then changed to step down media for 48 hours and 
treated with compounds of interest followed by in vitro Solute Flux assay as described above. 
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2.4 Results  
2.4.1 Activation of EPAC Prevents VEGF and TNF-α-Induced Permeability and Reverses 
Ischemia Reperfusion-Induced Permeability In Vivo. Activation of the EPAC-Rap1 signaling 
pathway via the EPAC specific cAMP analog, 8-CPT-2′-O-Me-cAMP, regulates barrier 
properties in endothelial cells such as HUVEC, pulmonary endothelial cells and in rat mesenteric 
microvasculature [187, 188, 190]. However, little is known about the role of EPAC-Rap1 
signaling in the endothelial cells of the BRB or the relation of EPAC-Rap1 signaling to vascular 
permeabilizing factors such as VEGF and TNF-α. Long-Evans rats were utilized to determine if 
pharmacological activation of the EPAC-Rap1 signaling pathway prevents retinal vascular 
permeability in vivo. First, to determine the localization of Rap1 expression in retinas, 
immunofluorescent staining of rat retinas was performed using an anti-Rap1 antibody, which 
binds both the Rap1A and B isoforms; retinas were co-stained with IB4 to identify blood vessels. 
Rap1 was located only in the capillary vessels and colocalizes with IB4 staining (Figure 2.1.A). 
Next, VEGF and TNF-α were intravitreally co-injected into Long-Evans, rats and 3 hours later, 
Evan’s blue was administered through the femoral vein to assess Evan’s blue dye accumulation 
in the retina tissue as a measure of retinal vascular permeability. VEGF and TNF-α increased 
retinal vascular permeability by two-fold in comparison to control (Figure 1B). The retinas that 
were intravitreally co-injected with either 10µM or 50µM of 8CPT-AM, along with both VEGF 
and TNF-α, had no significant increase in retinal vascular permeability compared to controls, 
showing that 8CPT-AM treatment blocks VEGF/TNF-α-induced permeability (Figure 2.1.B). To 
determine if activation of the EPAC-Rap1 signaling pathway can restore barrier properties to the 
retinal vasculature, an ischemia reperfusion model was used. In rodent models, ischemia 
reperfusion (IR) rapidly induces a VEGF dependent increase in retinal vascular permeability, 
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which persists for at least 48 hours and leads to expression of a host of inflammatory factors 
[65]. IR was induced in mice and 48 hours later, 8CPT-AM was administered intravitreally and 
retinal vessel permeability was compared to vehicle-injected control eyes. The 100µM 8CPT-
AM concentration used for intravitreal injection was a dose shown to activate EPAC independent 
of PKA activation in retinal pigment epithelium (RPE) and choroid [185, 217] and was shown to 
not increase PKA activity (Figure 2.S1.A). Animals with ischemia displayed a 2-fold increase in 
retinal vascular permeability (Figure 2.1.C) as previously observed in rat [65]. Mice that received 
intravitreal injection of 100µM 8CPT-AM after ischemia showed a reversal of ischemia-induced 
retinal vascular permeability by measuring accumulation of FITC-BSA (Figure 2.1.C) or 70kDa 
Dextran-Texas Red in the retina, (Figure 2.S1.B).  
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Figure 2.1 Cyclic AMP Analog, 8CPT-AM, Regulates Retinal Vascular Permeability.  
A. Rap1 is found in the capillary plexus of the retina. Immunofluorescence analysis was 
utilized to detect the presence of Rap1 (green) in rat retina. IB4 vascular marker (purple) and 
Hoechst nuclear stain was used. Ganglion cell layer (GCL), inner nuclear layer (INL), outer 
plexiform layer (OPL), outer nuclear layer (ONL). Scale bar 75µm and 25µm for zoom 
image. B. 8CPT-AM blocks retinal vascular permeability. Long-Evans rats received 
intravitreal co-injection of VEGF (50ng) and TNF-α (10ng) or 8CPT-AM at 355ng (an 
estimated vitreous concentration of 10µM) or 1.78µg (estimated 50µM) with VEGF and 
TNF-α and compared with vehicle control. After 3 hours, rats received a femoral vein 
injection of Evans Blue and retinal dye accumulation was determined. C. 8CPT-AM reverses 
ischemia reperfusion-induced permeability. Retinal ischemia in mice was achieved by 
increasing intraocular pressure with PBS delivered to the anterior chamber to prevent blood 
flow for 90 min followed by natural reperfusion. 48 hours later vehicle or 8CPT-AM at 278ng 
(estimated vitreous concentration of 100µM) was delivered by intravitreal injection and 
FITC-BSA dye accumulation was determined. Results are expressed as the mean relative to 
the control + S.E.M., Bonferroni post hoc test ##p < 0.01 compared to control. 
51 
 
2.4.2 Activation of the EPAC-Rap1 Pathway Prevents and Reverses VEGF or TNF-α  
Induced Endothelial Permeability. The EPAC-Rap1 signaling pathway in VEGF- or TNF-α-
induced endothelial permeability was examined in primary culture of bovine retinal endothelial 
cells (BREC). Western blotting reveals that EPAC and Rap1 proteins are expressed in BREC, 
(Figure 2.2.A). To validate that 8CPT-AMactivates the EPAC-Rap1 signaling pathway in these 
cells, we used the active Rap1 capture assay, which captures active, GTP-bound Rap1 through 
binding to a GST-linked peptide for the downstream Rap1 effector RalGDS. Confluent 
monolayers of BREC were treated with VEGF, or first pretreated with 8CPT-AM then VEGF or 
8CPT-AMalone, and compared to controls. BREC treated with 8CPT-AM (1µM) showed a 
significant 2.5-fold increase in Rap1 bound to GTP. One hour of VEGF had no apparent effect 
on Rap1 GTP loading with or without 8CPT-AM (Figure 2.2.B-2.C). To determine if longer 
exposure of VEGF affected the ability of 8CPT-AM to induce Rap1 GTP loading, BREC were 
stimulated with VEGF for 24 hours followed by 30 minutes of 8CPT-AM (1µM). Longer 
exposure of VEGF had no effect on Rap1 GTP loading and again 8CPT-AM alone or after 
VEGF induced a significant 2-3-fold increase in Rap1 activation (Figure 2.S2.A-S2.B). 
Additionally, a VEGF time response was performed to determine if VEGF directly affected 
active Rap1 levels in confluent BREC, but no differences in comparison to control were 
observed (Figure 2.S2.C-S2.D).  
Having established the ability of 8CPT-AM to activate EPAC/Rap in BREC, we tested 
whether activation of EPAC increases endothelial barrier properties and reverses permeability 
after VEGF or TNF-α. A dose response of 8CPT-AM was performed in BREC both with and 
without VEGF, and permeability to 70kDa RITC dextran was measured. 8CPT-AM at 
concentrations of 2µM, 1µM, and 0.5µM significantly reduced basal permeability in comparison 
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to control (Figure 2.2.D). To determine if 8CPT-AM was capable of blocking VEGF-induced 
retinal endothelial permeability, BREC were treated with varying doses of 8CPT-AM for 30 
minutes prior to VEGF (50ng/mL) and solute flux was measured beginning 30 minutes after 
VEGF addition. 8CPT-AM at the concentrations of 2µM, 1µM, and 0.5µM completely blocked 
VEGF-induced permeability (Figure 2.2.E). Based on these results, 1µM 8CPT-AM was used for 
all additional experiments unless otherwise stated.  
To verify that 1µM 8CPT-AM was specifically activating the EPAC signaling pathway 
independently of PKA signaling, we quantified phosphorylation of CREB, a downstream PKA 
target. BREC were stimulated for 1 hour with either 1µM or 100µM 8CPT-AM, or with 100µM 
forskolin (FSK) as a positive control to elevate cAMP (Figure 2.2.F). Cells were lysed and 
prepared for western blot. The BREC treated with FSK or with 100µM of 8CPT-AM had a 2-
fold increase in phosphorylation of CREB, but 1µM of 8CPT-AM did not increase 
phosphorylation of CREB (Figure 2.2.F) and quantified in (Figure 2.2.G).   
To address the question of whether activation of the EPAC-Rap1 signaling pathway can 
reverse permeability, we pretreated BREC with VEGF or TNF-α followed by 8CPT-AM and 
measured permeability to 70kDa RITC dextran using the solute flux assay. BREC were 
stimulated with VEGF alone, 8CPT-AM alone, pretreatment with 8CPT-AM 30 minutes prior to 
VEGF (pre-8CPT), or treatment with VEGF 30 minutes prior to 8CPT-AM treatment (post-
8CPT). As shown previously in (Figure 2.2.E), 8CPT-AM pretreatment (pre-8CPT) significantly 
blocks VEGF-induced permeability (Figure 2.3.A), and TNF-α-induced permeability (Figure 
2.3.B). Importantly, post-treatment with 8CPT-AM (post-8CPT) reverses VEGF-induced 
permeability (Figure 2.3.A). The combination of VEGF and TNF-α induces an additive 3-fold 
increase in endothelial permeability (Figure 2.3.C), and pretreatment with 8CPT-AM 
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significantly prevents combined VEGF/TNF-α-induced permeability as well as reverses the 
effects of both VEGF/TNF-α (Figure 2.3.C).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 8CPT-AM Rap1 Activation Prevents VEGF-Induced Permeability of BREC.  
A. Western blot analysis from BREC lysates shows the presence of the GEF EPAC1 and 
small G-protein Rap1. B. GTP bound Rap1 was determined by capture assay using GST-
RalGDS RBD. 8CPT-AM (1µM) was added 30 min prior to VEGF (50ng/mL) for a total 
time of 1.5 hours. Assay controls GTPS and GDP were added to lysates before capture. 
Quantification shown in C with a total n> 11. D. Solute flux assay was used to test 
permeability to 70kDa RITC dextran after 8CPT-AM at varying concentrations on BREC n> 
6 E. 8CPT-AM prevents VEGF-induced permeability. BREC stimulated with 8CPT-AM at 
doses indicated given 30 minutes prior to VEGF addition. Doses from 0.5µM to 2µM 
blocked VEGF-induced permeability. Average Po values for control were 7.1x10-7 and 
VEGF were 1.4x10-6(cm/s), total of n> 8. F. Low dose 8CPT-AM does not activate the PKA 
pathway. 8CPT-AM at 1µM was added to BREC for 1 hour and no increase in CREB 
phosphorylation was observed. Incubation of 8CPT-AM or Forskolin (FSK) at 100µM for 1 
hour increased CREB phosphorylation. G. Quantification shown in F with a total n>3. All 
results are expressed as the mean + S.E.M. relative to the control. One-way ANOVA and 
Bonferroni post hoc test #p < 0.05; ##p < 0.01; ###p < 0.001; ####p < 0.0001 compared to 
control in C, D, E, and G. **p < 0.01; ****p < 0.0001 compared to VEGF in C and E or 
8CPT-AM (1µM) in G. 
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Permeability to ions was also determined as a measure of paracellular permeability by 
measuring the transendothelial electrical resistance (TEER) in BREC monolayer using the ECIS 
system. The BREC cells were either pretreated or post-treated with 8CPT-AM (2µM) and the 
monolayer’s resistance was measured for 5 hours. BREC treated with VEGF display a 40% 
decrease in TEER compared to control (Figure 2.3.D). BREC pretreated with 8CPT-AM block 
VEGF from decreasing TEER, and BREC post-treated with 8CPT-AM reverse the effects of 
VEGF and increase TEER levels to control (Figure 2.3.D). To determine how long the 8CPT-
AM effect on VEGF reduction is maintained, we measured TEER for 24 hours. 8CPT-AM at 
1µM was statistically different from VEGF for 8 hours (Figure 2.S3.A) and a higher dose of 
8CPT-AM (5µM) was statistically different from VEGF for 16 hours (Figure 2.S3.B).  
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Figure 2.3 8CPT-AM Blocks and Reverses Permeability Induced by VEGF and TNF-α. 
A. BREC were stimulated with VEGF (50ng/mL) or/and 8CPT-AM (1µM). Pre-8CPT: 
BREC were stimulated with 8CPT-AM 30 min before VEGF treatment. Post-8CPT: BREC 
were treated with 8CPT-AM 30 min after VEGF. 70kDa RITC-dextran was added 30 min 
after the last treatment. Average Po values for control and VEGF were 9.7x10-7 and 1.7x10-
6(cm/s) respectively n> 6. B. BREC were pretreated for 30 min before stimulated with TNF-
α (10ng/mL) and 70kDa RITC-dextran was added 1h later. Average Po values for control and 
TNF-α were 1.1x10-6 and 1.7x10-6(cm/s) n> 12. C. BREC were stimulated with TNF-α 
(10ng/mL) for 1 hour followed by VEGF for 30 minutes. Pre-8CPT: (1µM) was added 30 
min before TNF-α+VEGF or Post-8CPT: (1µM) was added 1.5 hours after TNF-α+VEGF. 
70kDa RITC-dextran was added 30 min after the last treatment. Average Po values for 
control were 7.5x10-7 and for TNF-α+VEGF were 1.9x10-6(cm/s) n> 15. Results are 
expressed as the mean relative to the control + S.E.M. One-way ANOVA #p < 0.05; ##p < 
0.005; ###p < 0.001; ####p < 0.0001 compared to control. ****p < 0.0001 compared to VEGF, 
TNF-α, or VEGF+TNF-α in A, B, and C respectively. D. BREC were seeded on 8W10E+ 
arrays and TEER was measured every hour on the ECIS Z-theta instrument. 8CPT-AM 
(2µM) added 30 min prior to VEGF increases resistance and prevents VEGF-induced TEER 
loss for up to 6 hours. 8CPT-AM post-VEGF restores endothelial barrier after VEGF-
induced ion permeability. Data represents the mean + S.E.M. with analysis by two-way 
ANOVA Bonferroni post hoc test ****p < 0.0001 compared to VEGF, n = 3/group. 
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2.4.3 8CPT-AM Prevents and Reverses VEGF-Induced Tight Junction Disorganization. To 
assess the role of 8CPT-AM in junctional complex organization we performed 
immunofluorescence staining of BREC TJs. Cells were treated with VEGF (50ng/mL) for 1 
hour, 8CPT-AM (1µM) alone for 90 minutes, pretreated with 8CPT-AM for 30 minutes followed 
by 1 hour of VEGF, or treated with VEGF for an hour prior to 30 minutes of 8CPT-AM. VEGF 
induced significant disorganization, with large invaginations (arrows) and junctional border 
breaks (arrowheads) in all 3 TJ proteins analyzed (ZO-1, occludin, and claudin-5) (Figure 2.4.A) 
and as previously reported [216]. 8CPT-AM alone induced a significantly more linear and 
continuous organization of all 3 TJ proteins at the junctions in comparison to control as assessed 
by scoring in a blinded fashion (Figure 2.4.A). 8CPT-AM pretreatment blocked and post-
treatment reversed VEGF induction of TJ disorganization (Figure 2.4.A). It is notable that the 
increased cytoplasmic staining for both occludin and claudin-5 after VEGF treatment was not 
lost with 8CPT-AM post-treatment but the border organization was dramatically increased. To 
determine if 8CPT-AM or VEGF was causing a change in total TJ protein levels, we performed 
western blotting of the TJ proteins ZO-1, occludin, and claudin-5 after the same treatment with 
VEGF for 1 hour, 8CPT-AM for 90 minutes, or 8CPT-AM+VEGF. TJ proteins ZO-1, occludin, 
and claudin-5 (Figure 2.4.B-4.E) and adherens junction protein VE-cadherin (Figure 2.S4.A) 
showed no total protein changes in this short time course, suggesting that EPAC-Rap1 activation 
promotes TJ assembly at the border.  
2.4.4 8CPT-AM Attenuates VEGF Signaling. The mechanistic connection between 8CPT-AM 
and VEGF signaling was investigated by western blotting for phosphorylation of signal 
transduction proteins known to function downstream of VEGF. BREC were treated with VEGF 
(50ng/mL) for 15 minutes, 8CPT-AM (1µM) alone for 45 minutes, or pretreated with 8CPT-AM  
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Figure 2.4 8CPT-AM Prevents and Reverses VEGF-Induced Tight Junction Disorganization. 
A. Immunofluorescence staining of TJ proteins ZO-1, occludin, and claudin-5 was performed to 
assess their organization after the addition of 8CPT-AM (1µM) for 30 minutes and/or VEGF 
(50ng/mL) for 1 hour. Yellow arrows show loss of linear organization (invaginations), and yellow 
arrowheads show border breaks or gaps between adjacent cells. Histograms show scoring of TJ 
proteins as percent organization. ZO-1, occludin and claudin-5 border staining were quantified by 
semi-quantitative ranking score system based on a graded scale from 1 to 5: Grade 1 for near 
complete disorganization of border staining 0% to 25%, Grade 2 for 25% to 50% continuous 
border staining, Grade 3 for 50% to 75% continuous border staining, Grade 4 for 75% to 100% 
continuous border, and Grade 5 completely continuous border. B. Changes in TJ total protein 
expression with VEGF or 8CPT-AM were measured using western blot C- E. No changes in ZO-1, 
occludin, and claudin-5 expression were observed in any of the experimental conditions. Results 
are expressed as the mean relative to the control n> 4 with analysis by One-Way ANOVA and 
Bonferroni post hoc test, #p < 0.01; ##p < 0.005; ####p < 0.0001 or **** compared to VEGF.  
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for 30 minutes followed by VEGF for 15 minutes and compared to control cells. VEGF caused a 
significant increase in phosphorylation of both VEGFR2 (Tyr 1175) and Erk1/2 (Figure 2.5A-
5D). 8CPT-AM alone caused a 50% decrease in both Erk1 and Erk2 basal phosphorylation in 
comparison to control (Figure 2.5C-D). No phosphorylation changes were observed in VEGFR2 
between control and 8CPT-AM (Figure 2.5.B). However, pretreatment of 8CPT-AM 
significantly reduced the phosphorylation of both VEGFR2 (Tyr 1175) and Erk-1/2 in 
comparison to VEGF alone (Figure 2.5.B-D). This effect was specific, as both VEGF and 8CPT-
AM promote an additive increase in AKT (Ser 473) phosphorylation (Figure 2.5.E).  
 
 
 
 
 
 
 
Figure 2.5 8CPT-AM Attenuates VEGF-Erk1/2 Signal Transduction. A. 
Immunoblotting was used to detect phospho-Tyr 1175 and total VEGFR2, Phospho and 
total Erk ½, and phosphor-Ser 473 and total AKT changes in BREC pre-treated with 
8CPT-AM (1 µM) for 30 minutes followed by 15 minutes of VEGF (50ng/mL). B. 
VEGFR2 Y1175 phosphorylation was reduced by 8CPT-AM when added prior to 
VEGF n> 12. C. 8CPT-AM decreased Erk1 and D. Erk2 phosphorylation n> 10. E. 
Both VEGF and 8CPT-AM increase AKT phosphorylation n> 4. Values are means + 
S.E.M. ####p < 0.0001 or ### p < 0.001 or #p < 0.05 compared to control and ****p < 
0.0001 or **p < 0.01 compared to VEGF. 
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2.4.5 Inhibition of EPAC2 Increases Basal Permeability and Blocks 8CPT-AM Induction of 
Barrier Properties. To determine whether EPAC2 contributes to regulating basal permeability 
properties, the EPAC2 specific inhibitor, HJC0350, was used in a dose response solute flux 
assay. BREC were incubated with different HJC0350 concentrations for a total time of 45 
minutes. HJC0350 at 5µM and 10µM caused approximately a 2-fold permeability increase, 
(Figure 2.6). Inhibition of EPAC2 with HJC0350 at 5µM and 10µM blocked 8CPT-AM (1µM) 
from decreasing basal permeability. To determine potential cytotoxicity of HJC0350, a viability 
assay was performed. Viability of BREC treated with HJC0350, ESI 09 (an inhibitor of both 
EPAC1 and EPAC2), DMSO (50% as a positive control for BREC cytotoxicity), and VEGF 
(50ng/mL) were tested for 1.5 hours using the CellTiter-Fluor Cell Viability assay. VEGF, 
HJC0350 (0.1-50 µM), and ESI 09 (1-10 µM) did not cause cell death (Figure 2.S5), whereas 
50% DMSO caused ~75% cell death, and 30µM ESI 09 caused 33% cell death (Figure 2.S5).  
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Figure 2.6 EPAC 2 Antagonist Increases Basal Permeability and Blocks 
8CPT-AM Effect. Solute flux assay was used to test EPAC2 antagonist, HJC0350, 
at different concentrations on BREC. HJC0350 5µM to 10µM had a significant 
increase in basal permeability and blocked 8CPT-AM barrier induction. Average Po 
values for control and HJC0350 were 2.2x10-7 and 4.4x10-7(cm/s). Results are 
expressed as the mean + S.E.M. relative to the control with a total of n> 3, ####p < 
0.0001 or ##p < 0.001 compared to control and ****p < 0.0001; **p < 0.01; *p < 0.05 
compared to 8CPT-AM. 
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2.4.6 Rap1B Isoform Regulates Basal Permeability and Tight Junction Organization.  
Mammals possess two isoforms of EPAC proteins, EPAC1 and EPAC2, and two isoforms of 
Rap1 proteins, Rap1A and Rap1B [145, 173]. To determine if BREC express these isoforms of 
EPAC and Rap1, we designed primers for each isoform and performed PCR. BREC express 
mRNA for both Rap1A and Rap1B isoforms, as well as EPAC1 and EPAC2 isoforms (Figure 
2.7.A). Specific bovine Rap1B siRNAs were used to knockdown Rap1B in BREC. A composite 
of 3 Rap1B specific siRNAs (transfected at 100nM) caused a 66% Rap1 knockdown in BREC, 
as assessed by western blot (Figure 2.7.B). Note that the antibody detects both Rap1A and B, as 
no isoform-specific antibody was available. To determine the role of Rap1B in basal endothelial 
permeability, we silenced the Rap1B gene in BREC and measured permeability using the 70kD 
solute flux assay. BREC with scramble siRNA behaved comparably to wild type BREC in 
response to both VEGF and 8CPT-AM (Figure 2.7.C). BREC with Rap1B knockdown 
demonstrated a 2-fold increase in basal permeability comparable to VEGF treatment (Figure 
2.7.C); notably this response was also comparable to addition of the EPAC2 antagonist (Figure 
2.6). VEGF addition to BREC with Rap1B knockdown had no additional change in permeability. 
BREC with Rap1B knockdown had a significant decrease in basal permeability in the presence 
of 8CPT-AM, which could be due to the presence of Rap1A or Rap2 isoforms or failure of 
complete Rap1B knockdown (Figure 2.7.C). To ensure specificity of the composite Rap1B 
siRNA, the 3 siRNAs were tested individually and one of the siRNAs (Rap1B-1 siRNA) was 
found to yield a 58% knockdown of Rap1 expression (Figure 2.S6.A) comparable to the 
composite Rap1B siRNA. Rap1B-1 siRNA at 100nM again led to a significant increase in basal 
permeability in comparison to scramble siRNA control (Figure 2.7.D). 
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To determine if Rap1B contributes to TJ organization, we silenced Rap1B expression in 
BREC using siRNA followed by immunofluorescence staining of the TJ proteins ZO-1, 
Figure 2.7 Rap1B Contributes to Basal Permeability and Tight Junction Organization. A. Both Rap1 
(Rap1A and Rap1B) and EPAC (EPAC1 and EPAC2) isoforms were found to be present in BREC by PCR. B. 
Western blot shows that composite Rap1B (100nM) siRNA results in a 66% knockdown, Student’s t-test ####p < 
0.0001, n> 9. C. Solute flux assay was used to test permeability in BREC with Rap1B knockdown. Scramble and 
Rap1B siRNA at 100nM were used in BREC. Average Po values for scramble control and Rap1B siRNA control 
were 2.4x10-7 and 5.4x10-7(cm/s). D. Solute flux assay was used to test permeability in BREC with individual 
Rap1B-1 siRNA. Scramble and Rap1B-1 siRNA at 100nM were used in BREC. Average Po values for scramble 
control and Rap1B-1 siRNA control were 9.0x10-8 and 2.3x10-7(cm/s). E. Immunofluorescence staining of TJ 
proteins ZO-1, occludin, and claudin-5 was performed to assess the organization of TJ proteins after Rap1B 
knockdown with and without VEGF (50ng/mL) for 1 hour. Scale bar, 10µm. Histograms of scoring TJ show % 
organization of TJs. All results are expressed as the mean relative to the scramble control with a total of n> 4. ZO-
1, occludin, and claudin-5 border staining were assessed by semi-quantitative ranking score system based on scale 
grade 1 to 5. Immunofluorescence results are expressed as the mean relative to the scramble control n> 4 with 
analysis by One-Way ANOVA and Bonferroni post hoc test, ****p < 0.0001 compared to scramble control and ##p 
< 0.05; ###p < 0.001; ####p < 0.0001 compared to Rap1B siRNA VEGF. Permeability results are expressed as the 
mean + S.E.M. relative to the scramble control two-way ANOVA analysis and Bonferroni post hoc test *p < 0.1 
and ##p < 0.01 comparison between scramble and Rap1B or Rap1B-1 siRNA controls.  
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occludin, and claudin-5. Scramble siRNA had no effect on basal organization, and BREC treated 
with VEGF for 1 hour showed disorganization of all three TJ proteins (Figure 2.7.E). BREC with 
Rap1B knockdown showed a significant percentage of TJ disorganization in comparison to 
scramble siRNA control with invaginations (arrows) gaps (arrowheads) and regions of border 
separation between cells (white arrows) (Figure 2.7.E). The combination of VEGF and Rap1B 
knockdown showed an even greater effect on TJ disorganization in comparison to scramble 
siRNA with VEGF. Similar to the solute flux assay results, BREC with Rap1B knockdown 
treated with 8CPT-AM alone or with 8CPT-AM plus VEGF for 1 hour showed increased 
organization of the TJs at the cell border (Figure 2.S6.B). These results are likely due to the 
remaining Rap protein available to respond to 8CPT-AM. 
2.5 Discussion 
The present study provides compelling evidence that activation of the EPAC-Rap1 
signaling pathway via the cAMP analog, 8CPT-AM, promotes barrier properties in retinal 
vascular endothelial cells. Previous research on the role of EPAC-Rap1 signaling in barrier 
properties has focused on HUVEC and epithelial cells [138, 165]. In this work, we demonstrate 
that the GEF, EPAC2, and the small GTPase, Rap1B, regulate basal retinal endothelial barrier 
properties and contribute to the TJ complex organization. We demonstrate that activation of 
EPAC-Rap1 blocks permeability induced by VEGF and TNF-α both in cells and in vivo. 
Importantly, activation of EPAC-Rap1 reverses permeability induced by these cytokines in cell 
culture and reverses retinal vascular permeability induced by ischemia reperfusion in vivo. 
8CPT-AM activation of EPAC-Rap1 regulates TJ organization and reverses the effect of TJ 
disorganization by VEGF, which likely contributes to the control of endothelial barrier 
properties. We further show that 8CPT-AM specifically attenuates the VEGF-Erk signaling 
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pathway. Together these data indicate that EPAC-Rap1 signaling contributes to basal barrier 
properties and TJ organization of retinal endothelial cells and activating this pathway can restore 
barrier properties of the BRB. 
Previous studies support a role for activation of the EPAC-Rap1 signaling pathway in 
blocking permeability induced by permeabilizing agents. In vivo studies show that activation of 
the EPAC-Rap1 signaling pathway attenuates platelet-activating factor (PAF)-induced 
permeability in the mesenteric microvasculature [190] and inhibits VEGF-induced dermis 
vascular permeability [189]. Activation of the EPAC-Rap1 signaling pathway also has been 
shown to block thrombin-induced permeability in HUVEC [187]. Additionally, activation of the 
EPAC-Rap1 pathway restores barrier properties in endothelial cells and in blood vessels. For 
example, activation of EPAC-Rap1 reverses TEER decrease caused by TNF-α and transforming 
growth factor (TGF-β) in HUVEC [194]. Our study builds upon these previous reports 
demonstrating that activation of EPAC-Rap1 reversed IR-induced permeability in vivo and 
reversed VEGF- and TNF-α-induced permeability in BREC and in vivo. Together these data 
show pharmacologic activation of EPAC-Rap1 signaling promotes and restores the BRB.  
The EPAC1 and EPAC2 protein isoforms are both expressed in the retina [218]. In the 
endothelium, EPAC1, but not EPAC2, is expressed in HUVEC [188]. EPAC2 has been detected 
in human pulmonary aortic endothelial cells (HPAECs) [187], and we show that EPAC2 mRNA 
is present in BREC. EPAC1 is known for its involvement in regulating cell-cell junctions and 
endothelial barrier properties [165, 188], and EPAC2 has been observed in modulating neuronal 
activity [219]. Here, we show that EPAC2, in addition to EPAC1, plays a role in retinal 
endothelial barrier. In BREC, when EPAC2 is inhibited, basal permeability is increased and 
8CPT-AM cannot restore the barrier. In a previous study, it was observed that ischemic 
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retinopathy in EPAC2-deficient mice induced a more severe retinal edema and a larger 
expression of aquaporin AQP4 surrounding the blood vessels in the inner BRB in comparison to 
the EPAC1-deficient mice [220]. The EPAC2 and EPAC1-decificient mice, without ischemic 
retinopathy, appeared relatively normal in comparison to the wild type mice. Future studies may 
address the role of EPAC2 in BRB properties after cytokine challenge or diabetes. 
The Rap1B isoform contributes a major role in endothelial barrier regulation, 
vasculogenesis, and angiogenesis [180, 181]. Even though the Rap1 isoform proteins have a high 
protein sequence homology, mice gene deletion studies of the individual Rap1 isoforms show 
different viability outcomes. The Rap1A null mice were viable and had no size difference in 
comparison to wild type mice. On the other hand, the Rap1B null mice show an 80% embryonic 
lethality between embryonic (E) day 13.5 and 18.5 [179, 182]. Global or endothelial specific 
double Rap1A and Rap1B gene deletion is completely embryonic lethal and mice die within 
E10.5 to E15.5 [181]. Post-mortem analysis revealed that Rap1B and double Rap1A and Rap1B 
null mice manifested vascular hemorrhage [181, 184]. The Rap1B null viable mice exhibited 
defective angiogenesis, which led to a retardation in retinal neovascularization [184]. Consistent 
with these studies, we reveal that silencing the Rap1B protein in BREC was sufficient to induce 
an increase in endothelial permeability and disruption of the TJs. However, addition of 8CPT-
AM decreased solute flux and promoted TJ organization at the cell periphery in BREC with 
Rap1B knockdown. These data are unsurprising Rap1A as well as Rap2A/B/C, or residual 
Rap1B from incomplete knockdown, may compensate with the pharmacologic dose of 8CPT-
AM and EPAC activation. 
   Activation of the EPAC-Rap1 pathway contributes to endothelium barrier properties 
through junction complex maintenance [221] and down regulation of small G-protein RhoA, 
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known to be involved in permeability [131]. EPAC activation in HUVEC leads to the 
recruitment of VE-cadherin to the cell border and formation of long linear and continuous 
adherens junctions [187]. VE-cadherin-mediated junctional organization in HUVEC results in a 
decrease in solute flux [188]. Additional observations of EPAC-Rap1 activation include 
reduction of actin stress fiber formation, and maintenance of VE-cadherin and cortical actin at 
the cell periphery [187]. Here, we show for the first time in BREC that EPAC-Rap1 signaling 
protects TJ organization of the proteins ZO-1, occludin, and claudin-5. EPAC-Rap1 signaling 
blocks and reverses VEGF-induced TJ invaginations, gap formations, and TJ border breaks. As it 
has been observed with VE-cadherin organization [187, 188], we also observed that 8CPT-AM 
alone increases the recruitment and continuous linear organization of TJ at the cell border but 
does not increase TJ protein expression.  
The mechanism by which activation of EPAC-Rap1 recruits and maintains TJ proteins at 
the cell borders of BREC remains to be fully understood. However, studies in endothelial cells 
show that organization and stabilization of the adherens junctional complex proteins may occur 
through the recruitment and interaction of afadin (AF-6) and Krev interaction trapped 1 (Krit1) 
with active Rap1 [192, 222]. In human pulmonary artery endothelial cells (HPAEC), activation 
of Rap1 promotes colocalization of AF-6 with both VE-cadherin and ZO-1 and interaction 
between AF-6 and p120-catenin [192]. In HUVEC active Rap1 recruits Krit1 to the cell-cell 
junctions, which interacts with β-catenin, p120-catenin, and AF-6 but not with ZO-1 [222]. 
Therefore, additional studies are necessary to determine if EPAC-Rap1 activation mediates TJ 
recruitment and organization in BREC via AF-6.    
Permeabilizing agents such as VEGF, TNF-α, and thrombin all activate RhoA [154, 187, 
192]. Activation of RhoA induces stress fiber formations associated with junctional complex 
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alterations and formation of intercellular gaps resulting in increased permeability [223]. 
Inhibition of RhoA downstream targets such as RhoA/Rho kinase (ROCK) blocks permeability 
[154]. In HUVEC, activation of EPAC-Rap1 signaling reduced permeability induced by 
permeabilizing agents by down regulating RhoA activity [187]. Studies in HUVEC show that 
active Rap1 interacts with rasip1 and together with Rap associating with DIL domain (radil), 
recruits Rho GTPase-activating protein 29 (ArhGAP29), which down-regulates RhoA activity 
[146]. Recently, it has been observed that rasip1 and radil are recruited to the cell membrane via 
the transmembrane protein heart of glass 1 (HEG1) [202]. An interesting finding from this group 
showed that interaction of Rap1-rasip1 and rasip1-radil-ArhGAP29 was not affected by HEG1 
knockdown. Immunofluorescent studies show that rasip1 has a perinuclear localization [195] but 
moves to the cell border during nascent junction formation after a calcium switch assay [201]. 
Together these data suggest that rasip1 serves a dual function, to interact with radil and 
ArhGAP29 to suppress RhoA activity and localizing to the cell border through HEG1 where it 
regulates recruitment and stabilization of junctional proteins, for mechanism schematic refer to 
[224].  
Studies of the outer retina show that Rap1 activation promotes barrier integrity in the 
retinal pigment epithelium (RPE) and inhibits choroidal neovascularization [217, 225]. In a 
retinal epithelial cell line (ARPE-19) Rap1 knockdown led to mislocalization of cadherins and a 
decrease in transepithelial electrical resistance (TER) [225] in a Rap1A specific manner [217]. 
Studies in RPE show that Rap1A regulates barrier integrity by modulating the interaction of β-
catenin and IQGAP, a scaffold protein involved in actin cytoskeleton and cell-cell adhesion 
regulation [226, 227]. This barrier stabilization inhibits choroidal endothelial cells transmigration 
[217, 228]. The results from the ARPE-19 cells and in vivo studies indicate that the Rap1A 
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isoform is the major contributor to RPE barrier integrity in contrast to the role of Rap1B in 
retinal vascular endothelial barrier properties observed here. These data suggest that individual 
Rap1 isoforms control barrier properties in a cell specific manner.       
Rap1 signaling regulates several cell processes including suppression of the Ras-Raf-Erk 
signaling pathway [229]. The extracellular signal-regulated kinase (Erk1/2) is involved in several 
cell pathways including but not limited to cell proliferation, cell survival, and migration [230]. In 
retinal endothelial cells, binding of VEGF to the VEGFR2 induces an increase in Erk1/2 
signaling. We showed that in BREC, activation of EPAC-Rap1 signaling attenuates the Erk1/2 
signaling and reduces the phosphorylation of the VEGFR2 on Tyr 1175. Previous studies have 
shown VEGFR2 activation leads to activation of the kinase, PKCβ, which phosphorylates 
occludin, promoting ubiquitination and leading to endocytosis of occludin and other junctional 
proteins, resulting in permeability [65, 74, 94]. Even though 8CPT-AM addition blocks VEGF-
induced permeability, 8CPT-AM does not attenuate phosphorylation of (S490) occludin (data not 
shown). 8CPT-AM treatment does block or prevent the internalization of junctional proteins 
suggesting either dominance of the junctional assembly pathway or inhibition of junctional 
internalization at a separate step.  
In conclusion, activation of the EPAC-Rap1 pathway, specifically the EPAC2 and Rap1B 
isoforms, contributes to both basal permeability and shows promise as a therapeutic strategy to 
restore barrier properties after VEGF or inflammatory cytokine induced permeability.  
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2.6 Supplement Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.S1 8CPT-AM Reverses Ischemia Reperfusion-Induced Permeability. 
A. 8CPT-AM was intravitreally injected in mice at various concentrations to 
determine if the PKA pathway is activated. The different doses of 8CPT-AM did 
not cause a difference in CREB phosphorylation in comparison to control, n>2. B. 
Retinal ischemia in mice was achieved by increasing intraocular pressure with PBS 
delivered to the anterior chamber to prevent blood flow for 90 min. 48 hours later 
vehicle or 8CPT-AM at 100µM (278ng) was delivered by intravitreal injection and 
permeability was determined by measuring accumulation of 70kDa Dextran-Texas 
Red in the retina. Results are expressed as the mean relative to the control + 
S.E.M., Bonferroni's post hoc test #p < 0.05 compared to vehicle sham. 
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Figure 2.S2 VEGF Does Not Alter Basal GTP-Bound Rap1 Levels in BREC. 
A. GTP bound Rap1 was determined by GTP-bound Rap1 capture assay using 
GST-RalGDS RBD. VEGF (50ng/mL) was added for 24 hours prior to 8CPT-
AM (1µM) for 30 minutes. Quantification shown in B. with a total n> 8. C. 
VEGF time course, 15 to 60 minutes, was performed on BREC. GTP-bound Rap1 
levels were determined using the capture assay and quantification shown in D.  
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Figure 2.S3 Higher Concentration of 8CPT-AM Maintains a High 
Resistance in BREC. BREC were seeded on 8W10E+ arrays and TEER 
was measured continually every hour on the ECIS Z-theta instrument. 
8CPT-AM at the different concentrations 1µM and 5µM maintained BREC 
TEER statistically significant higher than controls. A. 8CPT-AM (1µM) pre-
treatment is significantly different from VEGF treatment in BREC for 14 hr 
(*p<0.0001). B. 8CPT-AM (5µM) pre-treatment is significantly different 
from VEGF for at least 24 hr (*p<0.0001). 
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Figure 2.S4 8CPT-AM Does Not Alter VE-Cadherin Protein Expression. 
Changes in VE-cadherin total protein expression with VEGF or 8CPT-AM were 
measured using western blot. No changes in VE-cadherin expression were 
observed in any of the experimental conditions. Results are expressed as the 
mean relative to the control + S.E.M., n>4 per group with analysis by One-Way 
ANOVA with Bonferroni post hoc test. 
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Figure 2.S5 EPAC 2 Inhibitor, HJC0350, is Not Cytotoxic to BREC. BREC 
were incubated for 1.5 hours with 50% DMSO, VEGF (50ng/mL) and different 
concentrations of HJC0350 and ESI 09, an EPAC1 and EPAC2 inhibitor. The 
viability of cells was measured with a fluorogenic, cell-permeant, peptide substrate 
(GF-AFC). Results are expressed as the mean relative to the control with a total of 
n> 4 one-way ANOVA analysis and Bonferroni post-test ####P<0.0001. 
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Figure 2.S6 8CPT-AM Restores Tight Junction Organization in Rap1B Knockdown 
BREC. A. Western blot shows a 58% Rap1 knockdown with 100nM Rap1B-1 siRNA, 
Student’s t-test ####p < 0.0001, n>6. B. Immunofluorescence staining of TJ proteins ZO-
1, occludin, and claudin-5 was performed to assess the organization of TJ proteins after 
Rap1B knockdown and treated with 8CPT-AM for a total time of 1.5 hours or VEGF 
(50ng/mL) for 1 hour. Scale bar, 10µm.  
 
75 
 
CHAPTER 3 
Elucidating the Molecular Mechanism of aPKC Regulation of VEGF-Induced Retinal 
Vascular Endothelial Permeability 
 
3.1 Abstract 
VEGF signaling contributes to the pathology of eye diseases such as diabetic retinopathy 
(DR) by altering retinal vascular permeability. In VEGF signaling, both classical Protein Kinase 
C (cPKC) and atypical Protein Kinase C (aPKC) are activated. Recent studies have shown that 
inhibitors of aPKC isoforms zeta (ζ) and lambda (λ) block both VEGF and proinflammatory 
cytokine TNF-α-induced permeability. Moreover, studies in our lab have identified small 
molecule inhibitors specific for aPKC that prevent BRB breakdown. Remarkably, our data 
showed that these drugs effectively block both VEGF and TNFα-induced permeability, both in 
vitro and in vivo. However, the molecular mechanism by which aPKC regulates permeability 
remains unknown. The purpose of the present study is to identify downstream substrates of 
aPKC that are activated in the presence of VEGF and that induce changes to the retinal vascular 
permeability that result in loss of the BRB. To further explore the mechanism of VEGF-aPKC 
signaling, mass-spectrometry was used to identify phosphorylation changes regulated by VEGF 
and aPKC. Analysis of the phosphoproteome in primary retinal endothelial cell culture identified 
1,724 proteins. From these 1,724 proteins, 107 proteins showed a 25% phosphorylation change 
in response to VEGF and were repeated in more than one mass spectrometry analysis. Protein 
interaction networks were developed using Cytoscape, an open source software for visualizing 
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protein interactions. We identified a subnetwork consisting of the endothelial specific ras 
interacting protein, rasip1, and small GTPase proteins EPAC1 and Rap1. For future studies, we 
will focus on the role of aPKC and the EPAC-Rap1-rasip1 pathway to better understand the 
mechanisms involved in retinal vascular permeability. This research has the potential to provide 
strong mechanistic support for the use of aPKC inhibitors to treat retinal vascular permeability in 
a host of diseases, including DR.  
3.2 Introduction 
 Elevated growth factors such as vascular endothelial growth factor (VEGF) and pro-
inflammatory cytokines drive pathological changes in the permeability state of the blood-retinal 
barrier (BRB) during diseases like diabetic retinopathy [231]. Diabetic retinopathy (DR) is an 
eye complication that causes damage to all the cells of the retina. DR is a complication of 
prolonged diabetes that affects people with both type 1 and type 2 diabetes, and is the  leading 
cause of vision loss in people with diabetes [232]. An estimate of more than 200 million people 
have diabetes worldwide and about one third of these individuals show signs of DR [233]. It is 
estimated that by 2030, the prevalence of diabetes will double worldwide. This means that in the 
United States alone, an estimated 55 million Americans will have diabetes and 18 million will 
show signs of DR, costing the country more than $600 billion [234]. Available treatments for DR 
include photocoagulation, corticosteroids, and the most recently developed anti-VEGF therapies, 
which improve vision in about 40% of patients [232, 235]. However, these treatments have 
secondary complications, are invasive, inefficient, and are administered in later stages of the 
disease pathology, when vision has already been severely compromised. Thus, understanding the 
mechanisms involved in regulating retinal endothelial permeability will allow us to develop early 
detection methods, prevention techniques, and additional treatments against DR.  
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The VEGF family is comprised of several cytokines and receptors, which are 
fundamental in angiogenesis, vasculogenesis, endothelial cell biology, and vascular permeability. 
Mammals possess five VEGF isoforms: VEGF-A, -B, -C, -D, and PIGF (placenta growth factor) 
[236]. Additionally, several of these isoforms have splice variants, for example, VEGF-A has 
nine. The VEGF ligands bind with varying affinities to receptor tyrosine kinases (RTKs) called 
VEGF receptors (VEGFR) [237]. The VEGFRs consist of VEGFR1, also known as Fms-like 
tyrosine kinase-1 (Flt-1); VEGFR2, also known as fetal liver kinase-1(Flk-1) or kinase insert 
domain containing receptor (KDR) in human; and VEGFR3, also known as Fms-related tyrosine 
kinase 4 (FLT-4) [238]. The various VEGF isoforms and receptors have distinct roles. The most 
widely studied VEGFs are VEGF-A and its splice variant VEGF-A (165), both of which signal 
via the VEGFR2 to promote angiogenesis. 
In the vitreous of patients with leaky retinal blood vessels, elevated levels of VEGF and 
other pro-inflammatory cytokines are observed [239-241]. VEGF is known to drive both 
proliferation and vascular permeability. Ischemia in diabetic retinas causes an upregulation of 
chemokines that activate macrophages and microglia. Activated macrophages secrete angiogenic 
factors such as TNF-α, which can increase new vessel formation [242]. In addition, upregulation 
of TNF-α and macrophages can induce endothelial cells to release chemokines, such as 
monocyte chemoattractant protein-1 (MCP-1), VEGF, and interleukin-8 (IL-8) [243]. Another 
contributor to hypoxic conditions is the hypoxia inducible factor-1α and β (HIF-1α/β) complex 
which translocates to the nucleus, binds to the hypoxia response element (HRE) and upregulates 
VEGF transcription [244, 245]. Elevated levels of VEGF then increase angiogenesis and 
vascular permeability through both transcellular and paracellular pathways.       
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Studies focusing on the role of VEGF signaling in DR have elucidated some of its 
pathophysiology. VEGF-A can signal through either VEGFR1 or VEGFR2. The predominant 
secreted isoform, VEGF-A(165), binds VEGFR2, triggering dimerization of the receptor and 
activation of the cytoplasmic domain tyrosine kinase catalytic activity, resulting in 
phosphorylation of the tyrosine (Y) residues [246]. This leads to activation of several 
downstream signaling pathways that regulate proliferation, migration, survival, angiogenesis, 
and permeability [247]. The VEGFR2 tyrosine phosphorylation sites studied thus far include, but 
are not limited to, Y951, Y1054, Y1059, Y1214, and Y1175. The phosphosites Y951, 1054, and 
1059 are located in the receptor’s kinase domain, while Y1214 and 1175 are found in the 
receptor’s C-terminus [248]. Briefly, phosphorylation of Y951 serves as a binding site for 
proteins containing the Src Homology 2 (SH2) domain and has a role in regulating pathological 
angiogenesis through the binding of T cell-specific adapter molecule (TSAd) [249]. The 
autophosphorylation sites Y1054 and Y1059 are required for maximal kinase activity [250]. The 
autophosphorylation sites Y1214 and Y1175 serve as binding sites for SH2 domain proteins, 
which in turn activate several signal transduction pathways that regulate angiogenesis, 
vasculogenesis, cell proliferation, survival, and permeability [246]. 
Studies of VEGF signal transduction in endothelial cells have revealed that increase 
phosphorylation of tight junctional proteins like occludin and ZO-1 are associated with increased 
permeability [251]. In accordance with the above observations, diabetic mice show an increase in 
occludin phosphorylation, and VEGF intravitreal injection in rats increases ZO-1 
phosphorylation in the retina [216, 251]. Studies in BREC show that VEGF signaling activates 
the protein kinase C beta, PKCβ, which phosphorylates occludin at serine (S) 490 [216]. This 
leads to ubiquitination and endocytosis of occludin, fragmentation of tight junctions, and 
79 
 
ultimately an increase in permeability [74]. Similarly, in vivo studies show that VEGF signaling 
induces PKCβ activation which phosphorylates S490 occludin [94]. Phosphorylation of S490 
occludin is required for retinal neovascularization and retinal endothelial cell proliferation [96]. 
Additionally, recent studies have demonstrated that VEGF-induced permeability requires 
activation of atypical PKC (aPKC) [214], (Figure 3.1).  
The serine/threonine protein kinases, PKCs, belong to the AGC kinase super family 
[252]. The PKC family is divided into 3 subfamilies: classical PKC (cPKC), novel PKC (nPKC), 
and atypical PKC (aPKC). The aPKC subfamily consists of two isoforms, zeta (ζ) and iota (ι), in 
humans, and lambda (λ) in mice. The classical PKCs, such as PKCβ, are activated by 
diacylglycerol (DAG) and calcium, while the novel PKCs are activated by DAG, but are 
insensitive to calcium. The aPKCs are insensitive to both calcium and DAG [253]. Rather, the 
aPKCs are activated via the phosphatidylinositol 3-kinase pathway (PI3K) pathway, which 
activates the PH domain-dependent kinase 1 (PDK1). PDK1 can directly phosphorylate aPKC at 
the C-terminus [253]. Phosphorylation of Thr410/Thr412 on PKCζ/ι by PDK1 liberates the 
pseudo-substrate domain, allowing autophosphorylation of Thr560/Thr555, which results in a 
fully active kinase [254]. For a complete review of the PKC family and subfamilies, refer to 
[252]. 
Our lab has developed small molecule inhibitors specific for aPKC that prevent BRB 
breakdown. Remarkably, our data showed that these drugs effectively block both VEGF and 
TNFα-induced permeability, both in vitro and in vivo [214]. However, the molecular 
mechanisms of these aPKC inhibitors remain unclear. Mass-spectrometry and iTRAQ labeling 
were used to identify and characterize the effectors of aPKC, which was activated in response to 
the presence of VEGF. The phosphoproteome performed using BREC, identified 1,724 unique 
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phosphoproteins and 107 phosphoproteins within the criteria of a ~25% phosphorylation change 
that were repeated in at least 2 out of 3 experiments. These studies suggest a molecular 
association between aPKC, small GTPases, and rasip1 in regulating VEGF-induced retinal 
vascular endothelial permeability.  
3.3 Methods: 
3.3.1 Reagents: Recombinant human VEGF165 was purchased from R&D Systems 
(Minneapolis, MN, USA). PKCζ/ι myristoylated pseudosubstrate inhibitor was purchased from 
Calbiochem (Gibbstown, NJ, USA). Small molecule aPKC inhibitors were purchased from 
ChemBridge Corporation (San Diego, CA, USA), Sigma-Aldrich (St. Louis, MO, USA) or 
synthesized by Apogee, Inc. (Hershey, PA, USA).  
3.3.2 Cell Culture: Bovine retinal endothelial cells (BREC) were used for the mass spectrometry 
analysis. Briefly, BREC were grown on plates that were coated with 1ug/cm2 fibronectin 30 
minutes prior to seeding cells. BREC were grown to 95% confluence in MCDB-131 medium, 
supplemented with 10% fetal bovine serum (FBS), 22.5 µg/mL endothelial cell growth factor, 
120 µg/mL heparin, 0.01 mL/mL antibiotic/antimycotic. Then, cell culture media was changed to 
stepdown media, MCDB-131 supplemented with 1% FBS, 0.01 mL/mL antibiotic/antimycotic, 
and 100 nmol/L hydrocortisone, for 48 hours prior to experiment. The experimental cell culture 
set ups were: a) Control, consisting of BREC cells with vehicles, b) BREC cells incubated with 
VEGF, c) BREC cells incubated with aPKC inhibitor 30 minutes prior to VEGF for 15 minutes, 
and d) BREC cells incubated with aPKC inhibitor only.  
3.3.3 Mass Spectrometry Based Phosphoproteomics: The iTRAQ labeling, TiO2 enrichment, 
and mass spectrometry procedures were conducted at Wayne University under the supervision of 
Dr. Paul. M. Stemmer. First, BREC were grown to confluence and stepdown for 48 hours, then 
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treated with VEGF, aPKC inhibitor (diMeO), or treated with both diMeO+VEGF. The cell lysate 
samples were labeled with isobaric tag for relative and absolute quantitation (iTRAQ), which is a 
non-radioactive isotope. Then, phosphorylated peptides were enriched with titanium dioxide 
(TiO2). For protein quantification and identification, the matrix-assisted laser 
desorption/ionization (MALDI) time-of-flight (TOF) was used. This is a soft ionization and 
broad mass range technique which utilizes a laser energy absorbing matrix to create ions from 
macromolecules and minimize molecule fragmentation. The time of flight mass spectrometer 
separates the molecules based on the time it takes them to travel through the tube and reach the 
detector. The results from the mass-spectrometry were analyzed using the Scaffold proteome 
software versions 4 and PTM. Criteria for significant phosphorylation changes induced by VEGF 
were determined if the change was greater than 0.6 log base 2 relative to control and were 
repeated in at least 2 out of 3 experiments.  
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The mass spectrometry results are based on log base 2 (log2) 
Explanation log2(1) = 0 
Log2(1.5) = 0.6 
Our cut off at 0.25  
log2(x)= 0.25 = 20.25 = 1.189 
 
 
The formulas used on excel for the 2 different categories and 2 subcategories are the following: 
 
Table 3.1 Excel Equations for Categories 1 and Subcategories 2 
1A and 1B = IF(AND(V>$0.25$,V+I>$0.25$),“1A”,IF(AND(V<$-0.25$,V+I<$-0.25$), 
“1B”,””)) 
2A AND 2B = IF(AND(V>$0.25$, V/2>V+I), “2A”, IF(AND(V<$-0.25$, V/2<V+I),”2B”,””)) 
V=VEGF, V+I = VEGF + aPKC inhibitor 
 
 
 
Table 3.2 Definitions of Categories  
 
Categories Description 
1A Phosphorylation increased with VEGF 
1B Phosphorylation decreased with VEGF 
2A Phosphorylation increased with VEGF and was reversed by aPKC 
inhibitor 
2B Phosphorylation decreased with VEGF and was reversed by aPKC 
inhibitor 
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3.3.4 Cytoscape Analysis: Cytoscape is an open source platform that allows for visual protein 
interaction network models. The plug-ins are software components that add specific features to 
the software being utilized. The plug-in used for visualizing protein-protein interactions using 
the mass spectrometry results was the Michigan Molecular Interaction (MiMI). The MiMI plug-
in retrieves molecular interaction information from several databases, including BIND, DIP, 
HPRD, RefSeq, SwissProt, IPI and CCSB-HI1 and merges it into one location, the MiMI 
database [255]. The combination of Cytoscape and the MiMI plug-in allow the display of protein 
interaction network(s).  
Western Blot: The western blot assay was performed as described previously in Chapter 2 
Methods (Section 2.3.8, page #44).  
In Vivo Permeability Assays: The permeability assay was performed as described previously in 
Chapter 2 Methods (Section 2.3.3, page #41).  
In Vitro Permeability Assay: The permeability assay was performed as described previously in 
Chapter 2 Methods (Section 2.3.4, page #42).  
3.3.5 Immunoprecipitation: Immunoprecipitation was utilized to detect the aPKC-pThr560 site 
and phosphoserine rasip1 in BREC treated with VEGF. The lysate was centrifuged at 14,000 × g 
for 10 min, and the supernatant was transferred to another microcentrifuge tube. 750 ug of 
protein was subjected to a preclear with 100 μl of 1:1 slurry of Protein G-SepharoseTM 4 Fast 
Flow (GE Healthcare) for 1 h. After brief micro-centrifugation the supernatant was incubated 
with either 5 ug aPKC Ab (C-20) or rasip1 Ab for 2 h. Protein G beads were added, followed by 
further incubation for 1 h. The beads were recovered by centrifugation at 1500 × g for 1 min and 
washed four times with 1 ml of lysis buffer. Proteins bound to Protein G were eluted by boiling 
in Laemmli buffer for 5 min then used to Western blot, as described above.  
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3.4 Results 
3.4.1 VEGF-Induced Permeability Requires Activation of Atypical PKC. Permeability 
induced by VEGF signaling is known to activate PKCβ, which phosphorylates occludin and 
results in ubiquitination and endocytosis of occludin [216]. Inhibitors of PKCβ partially block 
VEGF-induced permeability, suggesting additional kinases are involved in VEGF-induced 
permeability. Recent studies show that in addition to PKCβ, aPKC are activated in the presence 
of VEGF [214]. Activation of aPKCs, PKCζ/ι, is determined by an increase in phosphorylation 
of the phosphosites pThr560/Thr555 and pThr410/Thr412 in PKCζ/ι. To determine if VEGF 
activates aPKC, a time response of VEGF was performed in rats. Rats were intravitreally 
injected with VEGF (50 ng/mL), and after 15 or 30 minutes, retinas were harvested and prepared 
for immunoblotting, (Figure 3.1.A). The data show that VEGF induces phosphorylation of 
pThr560/Thr555 PKCζ/ι in the retina after 15 minutes and 30 minutes (Figure 3.1.A) and 
pThr410/Thr412 PKCζ/ι (Figure 3.1.B). Similarly, BREC stimulated with VEGF show an 
increase in aPKC phosphorylation (Figure 3.1.C).  
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Figure 3.1. VEGF Signal Activates aPKC Both In Vivo and In Vitro. (A) VEGF was 
intravitreally injected for the indicated time and retinas were excised from Sprague-
Dawley rats. aPKC was immunoprecipitated where indicated and immunoblotted for the 
autophosphorylation residue, pThr560/Thr555. (B) VEGF was intravitreally injected for 
15 min and retinas were excised from Sprague-Dawley rats. aPKC was 
immunoprecipitated where indicated and immunoblotted for the pThr410/Thr412. 
Quantitation of the results (mean ± SEM) from three independent experiments and are 
expressed relative to the control with a total of n≥8. *, p<0.05, **p<0.01. (C) BREC were 
treated with VEGF (50 ng/mL) and lysates were subjected to immunoblotting for 
pThr410/Thr412 and pThr560/Thr555 PKCζ/ι, and aPKC. Quantitation of the results are 
expressed as the mean relative to the control, error bars represent ± SEM. n≥8. *, p<0.05, 
** p<0.01. (Image adapted from Titchnell et al., 2012) 
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3.4.2 Inhibition of aPKC Blocks VEGF-Induced Permeability. Knockdown of aPKCi as well 
as expression of dominant negative aPKC and a peptide inhibitor to aPKC all block VEGF 
induced endothelial permeability [214]. The small molecule aPKC inhibitors were identified in a 
drug screen [214, 256] (Figure 3.2). Administration of VEGF intravitreally in rats induces a 
significant increase in retinal vascular permeability, but co-administration of VEGF and the 
aPKC inhibitor (aPKC-I-PD) blocks VEGF-induced permeability (Figure 3.3.A). Similarly, 
addition of VEGF on BREC increases permeability by 2.5-fold, and co-administration of VEGF 
and aPKC inhibitor (aPKC-PS) significantly blocks VEGF-induced permeability (Figure 3.3.B). 
 
 
 
 
 
 
 
 
 
Figure 3.2 Identification of Small Molecule aPKC Inhibitors. An aPKC inhibitor 
pharmacophore (aPKC-I-Pharmacophore) depicts regions of substitutions R3, R4, 
and R5. Three drugs were identified and further studied: PD (pro-drug) (aPKC-I-PD), 
dichloro-substituted phenyl ring (aPKC-I-diCl), and dimethoxy-substituted phenyl-
thiophene (aPKC-I-diMeO) (Figure from Titchenell et al., 2012). 
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3.4.3 1,724 Responsive Phosphoproteins Identified Downstream of VEGF Signaling. To 
identify effectors of aPKC downstream of VEGF signaling, mass spectrometry (MALDI-TOF) 
was used. BREC were set up into 4 experimental settings: 1) control, 2) VEGF, 3) VEGF+aPKC 
inhibitor (diMeO), and 4) diMeO alone. After harvesting the cells, labeling with iTRAQ and 
reducing the lysates with TiO2, samples were subjected to MALDI-TOF mass spectrometry. 
From 3 separate mass spectrometry analyses, 1,724 unique phosphoproteins responsive to VEGF 
signaling were identified (Table 3.3.A). VEGF signaling induced both increases and decreases in 
phosphorylation. The proteins responsive to VEGF were divided into 2 main categories: 1A 
show a protein phosphorylation increase in the presence of VEGF and 1B show a protein 
phosphorylation decrease in the presence of VEGF. These categories were further subdivided 
into subcategories: 2A show proteins with phosphorylation increase in the presence of VEGF 
that was reversed by aPKC inhibitor and proteins in 2B show a phosphorylation decrease in the 
presence of VEGF that was reversed by aPKC inhibitor (Table 3.3.B).  
To narrow our results, the total phosphoproteins in each of the 3 mass spectrometry 
analyses were compared to select proteins identified in more than one mass spectrometry 
analysis. We identified a total of 107 phosphoproteins that were present in more than one 
analysis and had a 25% phosphorylation change in the presence of VEGF. Like the results above, 
the results of the 107 phosphoproteins containing a total of 139 phosphosites, were arranged by 
categories (Table 3.4). In category 1A, 67 phosphosites were identified and from these 37 
phosphosites were reversed in the presence of the aPKC inhibitor, subcategory 2A. In category 
1B, 72 phosphosites were identified from which 47 were in category 2B.  
3.4.4 Visual Protein-Protein Networks. Protein interactions of the 107 phosphoproteins were 
visualized using the Cytoscape bioinformatic tool and the plug-in MiMI. The input of the 107 
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phosphoproteins into Cytoscape gave us a large visual protein interaction network consisting of a 
total of 1,054 nodes and 21,069 Edges. The Nodes represent proteins and the Edges represent 
protein interactors (Figure 3.4). The use of Cytoscape allowed us to identify another subcategory 
of proteins that responded to VEGF signaling, those that had at least one site exhibiting increased 
phosphorylation and a site that showed a decreased in phosphorylation; these are represented by 
the color fuchsia. The octagon symbol represents phosphoproteinsin either category (1A or 1B) 
whose phosphorylation were reversed in the presence of the aPKC inhibitor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. aPKC Inhibitors Block VEGF-Induced Permeability In Vivo and In Vitro. 
(A) aPKC-inhibitor blocks VEGF induction of retinal vascular permeability in vivo. 
Sprague-Dawley rats were injected intravitreally with (25 μM) aPKC-I-PD, aPKC 
inhibitor. After 3 hours, rats received a femoral vein injection of 45 mg/kg Evans blue. 
After 2 hours, animals were perfused with citrate/paraformaldehyde buffer for 2 min, 
retinas removed, dried and Evans blue extracted with formamide. Evans blue was 
quantified on a spectrophotometer and normalized to plasma levels measured pre-
perfusion. Permeability was calculated and expressed as μl plasma/g dry weight/h 
circulation. The results are expressed as the mean relative to the control, error bars 
represent ± SEM. n≥8 per group, * p<0.05. (B) aPKC peptide inhibitor blocks VEGF-
induced permeability in endothelial cells. BREC were grown to confluence on 0.4 μm 
Transwell filters then stepped-down for 24 h. BREC were treated for 30 min with 50 nM 
aPKC pseudo-substrate as a peptide inhibitor (aPKC-PS) prior to 30 min treatment with 50 
ng/ml VEGF where indicated. Permeability of the monolayer to 70kDa RITC-Dextran was 
measured. n≥4. The results are expressed as the mean relative to the control, error bars 
represent ± SEM. ***, p<0.001; *, p<0.05. (Image adapted from Titchnell et al., 2012)  
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3.4.5 Rasip1 Protein Interaction Subnetwork.  
To narrow our search within the large network, we used the plug-in named Enhance Search, 
which permits us to focus on one particular protein and identify its primary interactors. We 
applied this search to several of the 107 proteins with a major focus on the endothelial specific 
ras interacting protein 1 (rasip1). Rasip1 was of particular interest because it has been observed 
to play a significant role in vasculogenesis, lumenogenesis, and in endothelial cell barrier 
properties. Here, we observed that rasip1 interacts with 6 primary interactors which include 
Rap1A, Rap2A, and 4 isoforms of Ras. Additionally, secondary interactors of rasip1are EPAC1, 
Figure 3.4 Visual Cytoscape Protein-Protein Interaction Network. Cytoscape was used 
to visualize protein interaction network of the 107 phosphoproteins. The nodes represent 
proteins comprise of the 107 phosphoproteins identified in Table 2, primary interactors 
which bind directly to our 107 proteins, and secondary interactors are proteins that interact 
with primary interactor proteins. Edges are the lines that connect 2 or more nodes and they 
depict protein interactions.  
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afadin, and SMARCA4, which are all from our 107-phosphoprotein list. Other secondary 
interactors of interest observed are ArhGAP29, EPAC2, RapGEF1 and 2, (Figure 3.5).       
 
 
 
 
 
 
 
 
 
Table 3.3 Mass Spectrometry Results (A) Three mass spectrometry analyses were 
performed, Exp. A through C. Each Exp. section shows the total proteins and the total 
phosphosites identified in each mass spectrometry analysis. (B) Phosphosites categories: 
Results are based on log base 2 (log2). Explanation: log2(1) = 0, Log2 (1.5) = 0.6, our cut 
off at 0.25; log2(x) = 0.25 = 20.25 = 1.189. Definitions: Category 1A Phosphorylation 
increases in the presence of VEGF. Category 1B phosphorylation decreases in the presence 
of VEGF. Subcategories: Category 2A Phosphorylation increases in the presence of VEGF. 
Protein phosphorylation is reversed by aPKC inhibitor. Category 2B Phosphorylation 
decreases in the presence of VEGF. Protein phosphorylation is reversed by aPKC inhibitor.   
Table 3.4 Identification of 107 Phosphoproteins Repeated in Mass Spectrometry 
Analyses. Analysis of phosphoproteome in BREC identified 1,724 phosphoproteins 
responsive to VEGF. From these 1,724 phosphoproteins, 107 proteins had their 
phosphorylation reversed in the presence of the aPKC inhibitor. From these 107 
phosphoproteins, 139 phosphosites were identified.  
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3.4.5 Phosphosites Consistent in 2 or More Mass Spectrometry Results. The protein rasip1 
shows an increase in phosphorylation at S419 in the presence of VEGF. Addition of the aPKC 
inhibitor shows a reversal of this phosphosite (Table 3.5.A). EPAC1 shows a decrease in 
phosphorylation on S864, which is reversed in the presence of the aPKC inhibitor. To determine 
if the rasip1 residue S419 is conserved among different species, we aligned the rasip1 bovine 
amino acid sequence 409-429. The sequence identity among species was above 90%; S419 was 
conserved in all 4 species (Table 3.6.B).  
Figure 3.5 Visual Rasip1 Protein Interaction Subnetwork Obtained Through 
Cytoscape and MiMI Plugin. Cytoscape and plugin MiMI were used to visualize the 
protein-protein interaction network of rasip1. This analysis identified a subnetwork 
consisting of small GTPase proteins such as rasip1, EPAC, Rap1, and afadin.  
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The phosphosite, S864, in EPAC is found within the RasGEF domain, and S419 in rasip1 
is found within the FHA domain, (Figure 3.6.A). To determine if phosphorylation changes occur 
in rasip1 after VEGF addition we performed immunoprecipitation studies in BREC. Preliminary 
studies show that immunoprecipitated rasip1 from BREC lysates treated with VEGF has an 
increase in phosphoserine in comparison to control (Figure 3.6.B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5 Rasip1 and EPAC Repeated Phosphosites Identified in the Mass 
Spectrometry. A. Rasip1 S419 was increased in the presence of VEGF and reversed 
with aPKC inhibitor (diMeO). EPAC1 S864 was decreased in the presence of VEGF 
and reversed in the presence of the aPKC inhibitor. These phosphosite changes were 
observed in two or more mass spectrometry results. B. Rasip1 bovine amino acid 
sequence from 409-429 were aligned with human, mouse, and rat rasip1 sequence and 
show a high sequence identity. The S419 is conserved in all 4 species. 
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Figure 3.6 Locations of Phosphorylation Sites in EPAC1 and Rasip1 and IP of 
Phosphoserine-Rasip1. A. The S864 in EPAC1 is found on the RasGEF domain. The 
S419 in rasip1 is found in the Forkhead-associated (FHA) domain a.a. 334-539. B. 
Immunoprecipitation of rasip1 from BREC treated with VEGF 30 min and incubated 
with phosphoserine antibody, show an increase in serine phosphorylation. Rasip1 is 
100 kD.   
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3.5 Discussion 
The epidemic of diabetes in the United States and worldwide will lead to a higher 
incidence of diabetic retinopathy, demanding new means of early detection, prevention, and 
treatments. Diabetic macular edema remains the clinical outcome most closely linked to vision 
loss in DR. Therefore, it is imperative to understand and characterize the normal and aberrant 
mechanisms that regulate permeability in the BRB.  
In the present study, we began to examine the mechanisms by which VEGF-aPKC 
signaling modulates retinal endothelial permeability. Here, we identified several phosphoproteins 
that responded to VEGF stimuli, and from these phosphoproteins, 107 were repeated in more 
than one mass spectrometry analysis. We identified specific phosphosites on both EPAC1 and 
rasip1 that were changed in the presence of VEGF and reversed in the presence of the aPKC 
inhibitor, suggesting that these changes in phosphorylation are regulated by aPKC activation. 
How these phosphorylation changes regulate the activity of either EPAC1 or rasip1 remains to be 
investigated. Moreover, the use of bioinformatic tools like Cytoscape and the plug-ins MiMI and 
Enhance Search identified several protein-protein interaction subnetworks, including one 
consisting of EPAC, rasip1, Rap1A, and afadin.   
The proteins identified, EPAC, rasip1, Rap1A, and afadin, in the Cystocape-MiMI 
protein-protein interaction subnetworks validate our results from Chapter 2. As shown in Chapter 
2, activation of the EPAC-Rap1 signaling pathway contributes to barrier properties of the BRB. 
Additionally, permeability induced by VEGF and/or TNF-α was blocked or reversed during 
EPAC-Rap1 signaling activation. Studies in HUVEC show that when active, Radil, a Rap1 
effector, recruits the GTPase-activating protein, ArhGAP29, to the cell border. Here, it is 
responsible for downregulating small GTPase activity [205]. Activation of Rap1 recruits both 
96 
 
Radil and rasip1 to the cell border and rasip1 then binds to the Radil-ArhGAP29 complex and 
downregulate rhoA activity [146, 205]. The phosphorylation increase on rasip1-S419 under 
VEGF signaling led us to ask if VEGF decreased the interaction between Rap1 and rasip1. 
Preliminary co-immunoprecipitation studies showed that VEGF did not reduce Rap1-rasip1 
interaction (data not shown). The mechanism of how VEGF inhibits rasip1 signaling remains 
unknown, but it is possible that since VEGF does not affect Rap1 and rasip1 interaction, it may 
affect rasip1-radil-ArhGAP29 interaction. This question should be addressed in the future via co-
immunoprecipitation studies using rasip1 S419 point mutant constructs.  
Another possibility as to how VEGF-induced phosphorylation of rasip1 inhibits its ability 
to help maintain the endothelial barrier is by blocking the interaction between rasip1 and the 
transmembrane protein Heart of Glass 1 (HEG1). Recently, de Kreuk et al., demonstrated that 
rasip1 moves to the cell border by binding to HEG1, and that loss of HEG1 prevents rasip1 
localization at cell borders of HUVEC [202]. They also determined that the region Forkhead-
associated (FHA) domain in rasip1, aa 334-539, is required to bind to HEG1. Interestingly, the 
phosphosite identified by our mass spectrometry, S419, falls within the FHA domain. Further 
studies will be required to determine if phosphorylation of rasip1-S419 affects rasip1 localization 
to the cell borders.  
  Overall, the mass spectrometry analyses identified 107 proteins that showed 
phosphorylation changes in the presence of VEGF and some of these phosphoproteins were 
reversed by the aPKC inhibitor. The subnetwork consisting of rasip1, EPAC, afadin, and Rap1A 
is only a small subset of the entire set of 107 phosphoproteins, and additional investigations 
should be performed on the additional proteins. These studies will facilitate our understanding of 
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the signal transduction mechanism of aPKC and rasip1 involved in retinal vascular permeability 
and potentially lead to new therapeutic options to control macular edema. 
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Chapter 4 
Conclusions and Future Directions 
Breakdown of the BRB occurs early in the development of DR, which contributes to the 
formation of lipid exudates, in addition to inducing hemorrhages, and macular edema [231, 257]. 
In ischemic diabetic retinas, permeability is observed, in addition to increased VEGF levels, new 
vessel formation, and inflammation [239]. Increased BRB permeability, combined with new 
vessel formation, angiogenesis, causes changes in the retina’s homeostasis, resulting in neuronal 
cell death and ultimately vision loss [258]. Over the last three decades, investigations into DR 
have identified targets such as VEGF and mechanisms like inflammation that contribute to an 
increase in permeability. Identification of VEGF and its involvement in regulating angiogenesis 
led to the development of antibodies that block VEGF and the progression of angiogenesis [235, 
259]. Additionally, administration of glucocorticoids shows a decrease in inflammation and 
edema, and improves visual acuity in patients [260, 261]. However, not all patients treated with 
anti-VEGF antibodies show improvement and glucocorticoid treatments are associated with 
secondary adverse complications, such as elevated intraocular pressure, glaucoma, and cataracts 
[262-264]. Therefore, additional investigation is required to identify new targets in DR, identify 
mechanisms that restore the BRB, and elucidate early DR mechanisms that will allow the 
development of early detection methods.       
In this thesis, I investigated the mechanisms that regulate retinal endothelial barrier 
formation and maintenance. There were two main objectives in this thesis. The first objective, 
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addressed in Chapter 2, was to elucidate the role of the EPAC-Rap1 signaling pathway in barrier 
formation and maintenance. The second objective, in Chapter 3, was to identify novel VEGF 
targets and aPKC effectors involved in retinal vascular permeability. The summary of our 
findings and future directions are discussed in the section below.   
Studies in endothelial cells, such as HUVEC, show that activation of the EPAC-Rap1 
signaling pathway contributes to barrier properties. Administration of cAMP or cAMP analogs 
that specifically target EPAC, activate Rap1, which promotes endothelial barrier strengthening 
and shows a decrease in basal permeability [189, 201]. Additionally, activation of the EPAC-
Rap1 signaling pathway has been observed to block permeability induced by platelet-activating 
factor (PAF) [190], TNF-α [187], and thrombin [187]. Mechanistically, activation of Rap1 
recruits rasip1 to cell borders, rasip1 in turn binds to the Radil-ArhGAP29 complex and this 
interaction leads to downregulation of RhoA activity [146, 205]. Active RhoA is associated with 
VEGF, TNF-α, and thrombin-induced permeability [155]. When active, RhoA activates the Rho 
kinase, ROCK1/2, which stabilizes the phosphorylated state of myosin light chain (MLC) and 
promotes interaction between actin and myosin. These results in actin stress fiber formation and 
actomyosin contractility, which increases tension at cell junctions causing gaps [138, 265]. 
Inhibition of RhoA or ROCK ameliorates permeability [154, 266].  
To our knowledge, the role of the EPAC-Rap1 signaling pathway in the retinal 
endothelial cells that form the iBRB, had not been investigated. Therefore, in Chapter 2, we 
investigated the role of the EPAC-Rap1 pathway in BREC and the retina. With the use of an 
improved cell membrane permeable cAMP analog, 8-pCPT-2´-O-Me-cAMP-AM (8CPT-AM), 
we investigated the role of the EPAC-Rap1 pathway in the BRB. Intravitreal administration of 
8CPT-AM blocked VEGF+TNF-induced permeability in rats. In mice, activation of the EPAC-
100 
 
Rap1 signaling pathway reversed IR-induced permeability. Similar to the results in HUVEC, we 
observed that activation of EPAC-Rap1 signaling decreased BREC basal permeability and 
blocked and reversed permeability induced by VEGF and TNF-α. These results suggest that the 
EPAC-Rap1 pathway contribute to the maintenance and restoration of the BRB.        
Increase in retinal vascular permeability has been associated with disruptions to TJs, 
special cell-cell contacts which help regulate movement through the paracellular space. Studies 
in DR and VEGF-induced permeability show a reduction in the TJ protein occludin [267]. VEGF 
has been observed to cause phosphorylation of the TJ proteins occludin and ZO-1 [251, 268]. 
Mechanistically, VEGF signaling activates PKCβ, which phosphorylates occludin at S490. 
Phosphorylated occludin is followed by ubiquitination and endocytosis [216]. Additionally, 
TNF-α-induced permeability is associated with loss of ZO-1 and claudin-5 and discontinuous 
occludin staining at cell borders [206]. Therefore, we used immunofluorescent staining to 
evaluate the role of EPAC-Rap1 signaling on the TJ proteins ZO-1, claudin-5, and occludin in 
BREC. Our results show that under basal conditions, activation of EPAC-Rap1 signaling 
promotes continuous linear TJ staining at the cell borders. Additionally, activation of the EPAC-
Rap1 signaling pathway blocks and reverses the TJ disruption induced by VEGF signaling. 
These data show that in BREC, the EPAC-Rap1 pathway confers barrier properties through 
stabilization and organization of the TJs at the cell borders. The specific mechanism of how 
activation of EPAC-Rap1 signaling regulates TJ assembly and stability at cell borders remains to 
be investigated. It is possible that TJ stability occurs through the scaffold protein afadin (AF-6), 
which is known to link junctional proteins to the cytoskeleton. In the presence of cAMP analogs, 
AF-6 staining has an increase in its continuity along cell-cell contacts [187], and it interacts with 
active Rap1, ve-cadherin and ZO-1 [269]. Additionally, active Rap1 is known to recruit KRIT-1 
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(CCM1), a junctional protein important in proper vascular function, which interacts with the AJ 
proteins p120-catenin and β-catenin. Loss of function mutations in KRIT1 result in vascular 
malfunctions [222]. Co-immunoprecipitation studies show that active Rap1 increases the 
interaction between KRIT-1 and AF-6 [222].     
The results in Chapter 2 show for the first time that EPAC2 plays a role in regulating 
basal permeability. Inhibition of EPAC2 induces an increase in permeability that cannot be 
restored by 8CPT-AM treatment (a drug known to activate the EPAC pathway). Additionally, we 
show that Rap1B regulates basal permeability and the organization of TJs, which are disrupted in 
Rap1B knockdown BREC. However, addition of 8CPT-AM to Rap1B knockdown cells showed 
a decrease in permeability, blocked VEGF-induced permeability, and restored TJ organization at 
cell borders. We propose that additional Rap isoforms like the Rap2 and Rap1A are activated by 
8CPT-AM and compensate for the lack of Rap1B. Further studies testing the roles of EPAC and 
Rap isoforms will allow us to identify specific differences in these isoforms and identify which 
ones contribute most to barrier formation and maintenance.  
TNF-α signaling activates aPKC, which is associated with retinal endothelial 
permeability [270, 271]. Inhibitors towards aPKC block TNF-α-induced permeability [206]. 
Recently, it was found that VEGF-induced permeability also requires activation of aPKC [214]. 
Inhibitors that target aPKC block both TNF-α and VEGF-induced permeability, suggesting that 
aPKC represents a common node in both TNF-α and VEGF signaling. However, the specific 
mechanisms in VEGF-aPKC permeability are not known. In Chapter 3, our objective was to 
further investigate the mechanism of VEGF-aPKC pathway and identify aPKC effectors.   
Our studies identified more than 1,700 unique phosphoproteins responsive to VEGF 
treatment from three independent mass spectrometry analyses. From the 1,724 proteins obtained, 
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107 phosphoproteins were observed in more than one analysis. We focused on the phosphosites 
that were changed with VEGF and reversed by the aPKC inhibitor, diMeO. We identified several 
of these proteins and focused on a subnetwork comprised of rasip1, Rap1A, EPAC, afadin, and 
the transcription factor, SMARCA4. We found that rasip1 is phosphorylated at S419 and EPAC 
is dephosphorylated at S864 in the presence of VEGF. The aPKC inhibitor reversed the 
phosphorylation changes induced by VEGF. The scaffold protein, afadin, showed both 
phosphorylation increases and decreases in the presence of VEGF, but only the decrease in 
phosphorylation induced by VEGF was reversed in the presence of the aPKC inhibitor.   
The results from the mass spectrometry work open many possibilities for future studies. 
The most interesting is the analysis of rasip1-S419 and the construction of rasip1-S419 point 
mutants. Future studies will address the question of whether overexpression of rasip1-S419D 
leads to permeability and if rasip1-S419A prevents permeability. Additionally, our laboratory 
will investigate the mechanism of rasip1-S419. Currently, we know that active Rap1 recruits and 
binds rasip1, and binding to HEG1 localizes rasip1 at the cell membrane. Some questions to 
address would be if rasip1-S419D blocks interaction between rasip1 and HEG1 or the interaction 
with the radil-ArhGAP29 complex in BREC.  
In conclusion, the studies presented in this thesis expand our knowledge on the role of 
EPAC-Rap1 signaling in promoting retinal endothelial barrier properties via TJs assembly at cell 
borders. We, also identified that EPAC2 and Rap1B contribute to basal endothelial barrier 
regulation. Rap1B regulates TJ cell border organization. We also identified several 
phosphoproteins responsive to aPKC. Inhibition of aPKC blocks both VEGF and TNF-α-induced 
permeability, thus aPKC effectors might represent common nodes between VEGF and TNF-α 
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signaling. Understanding the mechanisms that regulate barrier properties are of significance in 
developing novel ways to treat pathologies with leaky vessels.  
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